<!DOCTYPE html>
<html lang='en'>

<head>
<meta charset="utf-8">
<title>Linezolid Monograph for Professionals - Drugs.com</title>
<meta name="viewport" content="width=device-width, initial-scale=1">
<meta name="description" content="Linezolid reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).">
<meta name="referrer" content="origin-when-cross-origin">
<link rel='canonical' href='https://www.drugs.com/monograph/linezolid.html'>
<link rel='search' type='application/opensearchdescription+xml' href='/opensearch.xml' title='Drugs.com'>
<!-- Facebook Open Graph Summary -->
<meta property="fb:app_id" content="1470988726468809">
<meta property="article:author" content="https://www.facebook.com/Drugscom">
<meta property="article:publisher" content="https://www.facebook.com/Drugscom">
<meta property="og:title" content="Linezolid Monograph for Professionals - Drugs.com">
<meta property="og:image" content="https://www.drugs.com/img/social/ddc-opengraph-logomark.png">
<meta property="og:site_name" content="Drugs.com">
<meta property="og:locale" content="en_US">
<meta property="og:type" content="article">
<meta property='og:description' content="Linezolid reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).">
<meta property='og:url' content="https://www.drugs.com/monograph/linezolid.html">
<!-- Twitter Summary Card -->
<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@drugscom">
<meta name="twitter:title" content="Linezolid Monograph for Professionals - Drugs.com">
<meta name="twitter:image" content="https://www.drugs.com/img/social/ddc-opengraph-logomark.png">
<meta name='twitter:description' content="Linezolid reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).">
<!-- Favicons -->
<link rel='manifest' href='/manifest.json'>
<link rel='icon' type='image/png' sizes='32x32' href='/img/logo/favicon/ddc-icon-32x32.png'>
<link rel='icon' type='image/png' sizes='16x16' href='/img/logo/favicon/ddc-icon-16x16.png'>
<link rel='apple-touch-icon' sizes='180x180' href='/img/logo/favicon/apple-touch-icon-180x180.png'>
<meta name='theme-color' content='#259cd8'>
<!-- CSS -->
<style>body{margin:0;padding:0;}img{max-width:100%;height:auto;}.contentBox{overflow-wrap:break-word;word-wrap:break-word;}</style>
<link rel='stylesheet' href='/bundle/css/ddc-pack-site.min.fde32fb9.css'>
<link rel='stylesheet' href='/bundle/css/ddc-print.min.e6665d40.css' media='print'>
<!-- Schema -->
<script type='application/ld+json'>[{"@context":"http://schema.org/","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Professionals","item":{"@type":"MedicalWebPage","@id":"https://www.drugs.com/professionals.html"}},{"@type":"ListItem","position":2,"name":"AHFS Monographs","item":{"@type":"MedicalWebPage","@id":"https://www.drugs.com/monograph/"}},{"@type":"ListItem","position":3,"name":"Linezolid","item":{"@type":"MedicalWebPage","@id":"https://www.drugs.com/monograph/linezolid.html#"}}]},{"@context":"http://schema.org/","@type":"MedicalWebPage","@id":"https://www.drugs.com/monograph/linezolid.html","url":"https://www.drugs.com/monograph/linezolid.html","audience":{"@context":"https://schema.org","@type":"medicalAudience","audienceType":["Patient","Clinician","MedicalResearcher"]},"publisher":{"@context":"http://schema.org/","@type":"Organization","@id":"https://www.drugs.com/#organization","name":"Drugs.com","url":"https://www.drugs.com","logo":{"@context":"http://schema.org","@type":"ImageObject","url":"https://www.drugs.com/img/logo/schema/drugscom-logo-600x60.png","width":600,"height":60}},"image":{"@type":"ImageObject","contentUrl":"https://www.drugs.com/images/pills/nlm/00093-8244-34_NLMIMAGE10_FC43FE6F.jpg","url":"https://www.drugs.com/images/pills/nlm/00093-8244-34_NLMIMAGE10_FC43FE6F.jpg","caption":"Linezolid 600 mg"},"about":{"@type":"Drug","@id":"https://www.drugs.com/monograph/linezolid.html#linezolid","name":"linezolid","nonProprietaryName":"linezolid","pregnancyCategory":"http://schema.org/FDAcategoryC","pregnancyWarning":"Risk cannot be ruled out","prescriptionStatus":"http://schema.org/PrescriptionOnly","image":{"@type":"ImageObject","contentUrl":"https://www.drugs.com/images/pills/nlm/00093-8244-34_NLMIMAGE10_FC43FE6F.jpg","url":"https://www.drugs.com/images/pills/nlm/00093-8244-34_NLMIMAGE10_FC43FE6F.jpg","caption":"Linezolid 600 mg"}},"reviewedBy":{"@context":"http://schema.org/","@type":"Organization","@id":"https://www.drugs.com/#organization","name":"Drugs.com","url":"https://www.drugs.com","logo":{"@context":"http://schema.org","@type":"ImageObject","url":"https://www.drugs.com/img/logo/schema/drugscom-logo-600x60.png","width":600,"height":60}},"lastReviewed":"2021-03-01 00:00:00","name":"Linezolid","description":"Linezolid reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI)."},{"@context":"https://schema.org","@graph":[{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Overview","url":"https://www.drugs.com/mtm/linezolid-oral-injection.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Side Effects","url":"https://www.drugs.com/sfx/linezolid-side-effects.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Dosage","url":"https://www.drugs.com/dosage/linezolid.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Professional","url":"https://www.drugs.com/ppa/linezolid.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Interactions","url":"https://www.drugs.com/drug-interactions/linezolid.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Pregnancy Warnings","url":"https://www.drugs.com/pregnancy/linezolid.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Breastfeeding Warnings","url":"https://www.drugs.com/breastfeeding/linezolid.html"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"User Reviews","url":"https://www.drugs.com/comments/linezolid/"},{"@context":"http://schema.org/","@type":"SiteNavigationElement","name":"Drug Images","url":"https://www.drugs.com/linezolid-images.html"}]}]</script>
</head>

<body class='page-section-monograph page-doctype-content page-monograph-linezolid-html'>


<a class='ddc-skiplink-content' href='#content'>Skip to Content</a>


<header id="header">
	<div class="top-container">

		<div class="header-wrap container">
			<div class="header">

				<div class="brand">
					<a href="//www.drugs.com/">
						<img class='logo' src='/img/logo/drugscom-logo.svg' alt="Drugs.com" width='280' height='58' data-ga-category="Top Nav" data-ga-action="Logo">
					</a>
				</div>
				<form method='get' action='/search.php' class='search-main'>
					<div class="input-group-attached">
						<label class="ddc-form-label-placeholder" for="livesearch-main">Search Drugs.com</label>
						<input type="text" id="livesearch-main" name="searchterm" data-required="1" data-value="linezolid" class="livesearch webkit-speech" placeholder="Search" value="" maxlength="70" />

						<div class="search-filter">
							<div class="nav-facade-active header-select-wrapper">
								<span class="search-filter__label" data-value="search-alias=aps">
									<span data-search-select-value>All</span>
									<svg class='ddc-icon ddc-icon-down' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z' /></svg>								</span>
								<label>
									<span class="ddc-sr-only">Select the section you want to search in</span>
									<select name="sources[]" class="search-filter__select" data-search-select>
<option value=''>All</option>
<option value='consumer'>Consumer</option>
<option value='professional'>Professional</option>
<option value='drugimages'>Pill ID</option>
<option value='interactions'>Interactions</option>
<option value='news'>News</option>
<option value='fdaalerts'>FDA Alerts</option>
<option value='newdrugapprovals'>Approvals</option>
<option value='newdrugapplications'>Pipeline</option>
<option value='clinicaltrials'>Clinical Trials</option>
<option value='cg'>Care Notes</option>
<option value='natural'>Natural Products</option>
									</select>
								</label>
							</div>

						</div>

						<a href="#" class='search-close' role='button'>
							<span class="ddc-sr-only">Close</span>
							<span class='search-close-icon'>
								<svg class='ddc-icon ddc-icon-close' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M17 5.94L18.06 7l-5 5 5 5L17 18.06l-5-5-5 5L5.94 17l5-5-5-5L7 5.94l5 5 5-5z' /></svg>							</span>
						</a>

						<button class='ddc-btn'>
							<span class='ddc-sr-only'>Search</span>
							<svg class='ddc-icon ddc-icon-search' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M10 2a8 8 0 016.32 12.9l5.6 5.6-1.42 1.41-5.6-5.59A8 8 0 1110 2zm0 2a6 6 0 100 12 6 6 0 000-12z' /></svg>						</button>
					</div>

					<div class="ddc-link-no-visited search-browse">
						Browse all medications:
						<span class="alpha-list">
<a href='/alpha/a.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='a'>a</a>
<a href='/alpha/b.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='b'>b</a>
<a href='/alpha/c.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='c'>c</a>
<a href='/alpha/d.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='d'>d</a>
<a href='/alpha/e.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='e'>e</a>
<a href='/alpha/f.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='f'>f</a>
<a href='/alpha/g.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='g'>g</a>
<a href='/alpha/h.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='h'>h</a>
<a href='/alpha/i.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='i'>i</a>
<a href='/alpha/j.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='j'>j</a>
<a href='/alpha/k.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='k'>k</a>
<a href='/alpha/l.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='l'>l</a>
<a href='/alpha/m.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='m'>m</a>
<a href='/alpha/n.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='n'>n</a>
<a href='/alpha/o.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='o'>o</a>
<a href='/alpha/p.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='p'>p</a>
<a href='/alpha/q.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='q'>q</a>
<a href='/alpha/r.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='r'>r</a>
<a href='/alpha/s.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='s'>s</a>
<a href='/alpha/t.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='t'>t</a>
<a href='/alpha/u.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='u'>u</a>
<a href='/alpha/v.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='v'>v</a>
<a href='/alpha/w.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='w'>w</a>
<a href='/alpha/x.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='x'>x</a>
<a href='/alpha/y.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='y'>y</a>
<a href='/alpha/z.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='z'>z</a>
<a href='/alpha/0-9.html' data-ga-category='Top Nav' data-ga-action='Alpha' data-ga-label='0-9'>0-9</a>
						</span>
						<div class="search-browse-options">
							<a href="/search_advanced.html" data-ga-category="Top Nav" data-ga-action="Advanced Search">Advanced Search</a>
						</div>
					</div>
				</form>
				<nav class='ddc-nav-account'>
					<a class='ddc-btn ddc-btn-empty ddc-btn-sm ddc-btn-register' rel='nofollow' href='/account/register/'>Register</a>
					<a class='ddc-btn ddc-btn-secondary ddc-btn-sm' rel='nofollow' href='/account/login/'>Sign In</a>
				</nav>
				<div class='nav-block'>
					<a href='#' data-nav-toggle data-ga-category="Top Nav" data-ga-action="Hamburger" role='button'>
						<span class='ddc-sr-only'>Main navigation</span>
						<svg class='ddc-icon ddc-icon-menu' width='28' height='28' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M21 17v2H3v-2h18zm0-6v2H3v-2h18zm0-6v2H3V5h18z' /></svg>						<svg class='ddc-icon ddc-icon-close' width='32' height='32' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M17 5.94L18.06 7l-5 5 5 5L17 18.06l-5-5-5 5L5.94 17l5-5-5-5L7 5.94l5 5 5-5z' /></svg>					</a>
				</div>

			</div>
		</div>
	</div>


<nav class='ddc-nav'>
		<ul>
					<li class='ddc-nav-item'>
				<a href='/account/' rel='nofollow'>Account</a>
				<ul>
					<li><a href='/account/login/' rel='nofollow'>Sign In</a></li>
					<li><a href='/account/register/' rel='nofollow'>Register</a></li>
				</ul>
			</li>
					<li class='ddc-nav-item'><a href='/drug_information.html'>Drugs A-Z</a></li>
		<li class='ddc-nav-item'><a href='/pill_identification.html'>Pill Identifier</a></li>
		<li class='ddc-nav-item'><a href='/drug_interactions.html'>Interactions Checker</a></li>
		<li class='ddc-nav-item'><a href='/news.html'>News &amp; Alerts</a></li>
		<li class='ddc-nav-item'><a href='/professionals.html'>Pro Edition</a></li>
		<li class='ddc-nav-item'><a href='/sitemap.html'>More<span class='ddc-sr-only'> Resources</span></a></li>
	</ul>
</nav>

</header>


<div class='topbanner-wrap'>
<div id='drugs-drugs-1' class='display-ad display-ad-728x90'>
<script>
var ehs_ad_called = ++ehs_ad_called || 1;
</script>
</div>
<script src='//ads.ehealthcaresolutions.com/a/?adid=drugs-drugs-1&slotid=1&url=www.drugs.com%2Fmonograph%2Flinezolid.html&size=728x90&vpos=t&hpos=l&site=ehs.pro.drugs.drugs&drg=linezolid&drc=oxazolidinone_antibiotics&dra=1' defer></script>
	<button class='ddc-topbanner-close' data-toggle-class='.topbanner-wrap'>
		<span class='ddc-sr-only'>Close</span>
		<svg class='ddc-icon ddc-icon-close' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M17 5.94L18.06 7l-5 5 5 5L17 18.06l-5-5-5 5L5.94 17l5-5-5-5L7 5.94l5 5 5-5z' /></svg>	</button>
</div>

<main id='container' class='container'>

<div id='contentWrap' class='ddc-clear-both'>

<div id='content' class='content'>
<div class='contentHead'>
<nav class='ddc-breadcrumb' aria-label='breadcrumb'>
<ol class='ddc-breadcrumb-3'>
<li class='ddc-breadcrumb-item'><a href='/professionals.html'>Professionals</a></li>
<li class='ddc-breadcrumb-item'><a class='overflow' href='/monograph/'>AHFS Monographs</a></li>
<li class='ddc-breadcrumb-item active' aria-current='page'><span>Linezolid</span></li>
</ol>
</nav>
<div class='page-icons page-icons-header'>
<a href='#print' role='button' data-action='print' data-ga-category='social' data-ga-action='DDC' data-ga-label='Print Top'>
<svg class='ddc-icon ddc-icon-print' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M17.75 3.25v4h4v10.5h-4v3H6.25v-3h-4V7.25h4v-4h11.5zm-1.5 9.5h-8.5v6.5h8.5v-6.5zm4-4H3.75v7.5h2.5v-5h11.5v5h2.5v-7.5zm-4-4h-8.5v2.5h8.5v-2.5z' /></svg> Print
</a>
<a href='#save' role='button' data-action='share-mednotes' data-ga-category='social' data-ga-action='DDC' data-ga-label='Save Drug Top'>
<svg class='ddc-icon ddc-icon-save' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M19 15v2.75h2.75v1.5H19V22h-1.5v-2.75h-2.75v-1.5h2.75V15H19zM18 2.25c.9182 0 1.6712.7071 1.7442 1.6065L19.75 4v9h-1.5V4a.2501.2501 0 00-.1927-.2434L18 3.75H6a.2501.2501 0 00-.2434.1927L5.75 4v15.25h7v1.5H5a.7502.7502 0 01-.7432-.6482L4.25 20V4c0-.9182.7071-1.6712 1.6065-1.7442L6 2.25h12zM12.75 13.5V15H8v-1.5h4.75zm3.25-3V12H8v-1.5h8zm0-3V9H8V7.5h8z' /></svg> Save
</a>
</div>
</div>
<!-- google_ad_section_start -->

<div class="contentBox">
<div class='pronounce-title'><h1>Linezolid</h1><audio id='pronounce-audio' preload='none'>
  <source src='https://www.drugs.com/audio/mp3/1472-0.mp3' type='audio/mpeg'>
  <source src='https://www.drugs.com/audio/wav/1472-0.wav' type='audio/wav'>
</audio>
<a id='pronunciation' class='pronounce-icon' href='#pronunciation' title="Listen to audio pronunciation" onclick="document.getElementById('pronounce-audio').play();return false;"><svg class='ddc-icon ddc-icon-pronunciation' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M10.73 3.81a1.75 1.75 0 013.02 1.2v13.97a1.75 1.75 0 01-3.02 1.2l-4.2-4.43H3.24v-7.5h3.27zm1.39.99a.25.25 0 00-.3.04l-4.07 4.3v5.72l4.07 4.3c.03.03.07.05.11.06l.07.01c.14 0 .25-.1.25-.25V5.02a.25.25 0 00-.08-.18zm5.7 1.52A6.24 6.24 0 0121.25 12a6.24 6.24 0 01-3.43 5.68.75.75 0 11-.64-1.36A4.74 4.74 0 0019.75 12c0-1.9-1.03-3.59-2.57-4.32a.75.75 0 11.64-1.36zm-1.48 3c.87.45 1.41 1.51 1.41 2.68 0 1.17-.54 2.23-1.41 2.67a.75.75 0 01-.76-1.29l.08-.05c.32-.16.59-.69.59-1.33 0-.59-.23-1.08-.5-1.28l-.09-.05a.75.75 0 11.68-1.34zm-10.09.43h-1.5v4.5h1.5v-4.5z' /></svg></a></div>
<p class='drug-subtitle'><b>Class:</b> Oxazolidinones<br />
<b>VA Class:</b> AM900<br />
<b>Molecular Formula:</b> C<sub>16</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>4</sub><br />
<b>CAS Number:</b> 165800-03-3<br />
<b>Brands:</b> Zyvox</p>
<p class='ddc-reviewed-by ddc-author-ashp'><img src='/img/logo/vendor/ashp-logo-small.png' alt='' width='136' height='64'><span><a href='/support/editorial_policy.html#editorial-staff'>Medically reviewed</a> by Drugs.com on March 1, 2021. Written by <a href='/support/editorial_policy.html#ashp'>ASHP</a>.</span></p>
<ul class='ddc-anchor-links'>
<li><a class='ddc-link-no-visited' href='#uses'>Uses</a></li>
<li><a class='ddc-link-no-visited' href='#dosage'>Dosage</a></li>
<li><a class='ddc-link-no-visited' href='#cautions'>Cautions</a></li>
<li><a class='ddc-link-no-visited' href='#interactions'>Interactions</a></li>
<li><a class='ddc-link-no-visited' href='#pharmacokinetics'>Pharmacokinetics</a></li>
<li><a class='ddc-link-no-visited' href='#patient-advice'>Patient advice</a></li>
<li><a class='ddc-link-no-visited' href='#preparations'>Preparations</a></li>
</ul>

<h2>Introduction</h2>
<p>Antibacterial; oxazolidinone.    </p>
<h2 id='uses' class='ddc-anchor-offset'>Uses for Linezolid</h2>
<h3>Respiratory Tract Infections</h3>
<p>Treatment of community-acquired pneumonia (CAP), including infections associated with concurrent bacteremia, caused by susceptible <i>Streptococcus pneumoniae</i>.    </p>
<p>Treatment of CAP caused by susceptible <i>Staphylococcus aureus</i> (methicillin-susceptible [oxacillin-susceptible] strains only).     Also recommended for treatment of CAP caused by methicillin-resistant <i>S. aureus</i><a href="#unlbl-use">&dagger;</a> (MRSA; also known as oxacillin-resistant <i>S. aureus</i> or ORSA).  </p>
<p>Treatment of nosocomial pneumonia caused by susceptible <i>S. aureus</i> (including MRSA) or <i>S. pneumoniae</i>.   </p>
<p><i>Not</i> indicated for treatment of respiratory tract infections caused by gram-negative bacteria. It is imperative that an anti-infective active against gram-negative bacteria be used concomitantly if documented or presumed pathogens include gram-negative bacteria.</p>
<p>For information regarding treatment of pneumonia, including infections caused by MRSA, consult current IDSA clinical practice guidelines available at <a href="http://www.idsociety.org">[Web]</a>.  </p>
<h3>Skin and Skin Structure Infections</h3>
<p>Treatment of uncomplicated skin and skin structure infections caused by susceptible <i>S. aureus</i> (methicillin-susceptible [oxacillin-susceptible] strains only) or <i>S. pyogenes</i> (group A &beta;-hemolytic streptococci, GAS).  </p>
<p>Treatment of complicated skin and skin structure infections (including diabetic foot infections), without concurrent osteomyelitis, caused by susceptible <i>S. aureus</i> (including MRSA), <i>S. pyogenes</i>, or <i>S. agalactiae</i> (group B streptococci, GBS).    </p>
<p><i>Not</i> evaluated for use in the treatment of decubitus ulcers. </p>
<p><i>Not</i> indicated for treatment of skin and skin structure infections caused by gram-negative bacteria. It is imperative that an anti-infective active against gram-negative bacteria be used concomitantly if the documented or presumed pathogens include gram-negative bacteria.</p>
<p>For information regarding treatment of skin and skin structure infections, including infections caused by MRSA, consult current IDSA clinical practice guidelines available at <a href="http://www.idsociety.org">[Web]</a>.  </p>
<h3>Vancomycin-resistant Enterococcus faecium Infections</h3>
<p>Treatment of infections caused by susceptible vancomycin-resistant <i>Enterococcus faecium</i>, including infections associated with concurrent bacteremia.  </p>
<p>Has been used for treatment of native valve or prosthetic valve infective endocarditis<a href="#unlbl-use">&dagger;</a> caused by vancomycin-resistant or multidrug-resistant <i>E. faecium</i>. AHA recommends that patients with infective endocarditis attributable to enterococci resistant to penicillins, aminoglycosides, and vancomycin be managed by a team of specialists in infectious disease, cardiology, cardiovascular surgery, clinical pharmacy, and, if necessary, pediatrics.</p>
<p>For information on diagnosis and management of infective endocarditis and its complications, including anti-infective treatment of enterococcal endocarditis, consult current AHA guidelines available at <a href="http://my.americanheart.org/statements">[Web]</a>.</p>
<h3>CNS Infections</h3>
<p>Has been recommended as an alternative to vancomycin for treatment of CNS infections caused by MRSA<a href="#unlbl-use">&dagger;</a> (e.g., meningitis<a href="#unlbl-use">&dagger;</a>, brain abscess<a href="#unlbl-use">&dagger;</a>, subdural empyema<a href="#unlbl-use">&dagger;</a>, spinal epidural abscess<a href="#unlbl-use">&dagger;</a>). (See Pediatric Use under Cautions.)</p>
<p>For information regarding treatment of CNS infections caused by MRSA, consult current IDSA clinical practice guidelines available at <a href="http://www.idsociety.org">[Web]</a>.</p>
<h2 id='dosage' class='ddc-anchor-offset'>Linezolid Dosage and Administration</h2>
<h3>Administration</h3>
<p>Administer orally or by IV infusion.</p>
<p>When clinically appropriate, IV route may be switched to oral without dosage adjustment.</p>
<p>Avoid large quantities of foods or beverages with high tyramine content during linezolid treatment. (See Monoamine Oxidase Inhibition under Cautions.)</p>
<h4>Oral Administration</h4>
<p>Administer orally without regard to meals.</p>
<h5>Reconstitution</h5>
<p>Reconstitute powder for oral suspension at time of dispensing by adding amount of water specified on bottle to provide a suspension containing 100 mg/5 mL. After tapping bottle gently to loosen the powder, add water in 2 portions and agitate well after each addition.</p>
<p>Prior to administration of each dose, <i>gently</i> mix suspension by inverting bottle 3&ndash;5 times; do not shake.</p>
<h4>IV Administration</h4>
<p>For solution and drug compatibility information, see Compatibility under Stability.</p>
<p>Single-use containers of linezolid injection for IV infusion should be administered without further dilution. Do not use the containers in series connections; do not introduce additives into the solution.</p>
<h5>Rate of Administration</h5>
<p>Administer by IV infusion over 30&ndash;120 minutes.</p>
<h3>Dosage</h3>
<p>Safety and efficacy of &gt;28 days of linezolid treatment not evaluated in controlled clinical trials.</p>
<h4>Pediatric Patients</h4>
<h5>General Dosage for Neonates</h5>
<h6>Oral or IV</h6>
<p>Neonates: Manufacturer recommends 10 mg/kg every 12 hours initially in premature neonates &lt;7 days of age; may consider 10 mg/kg every 8 hours in those with inadequate response. Manufacturer recommends 10 mg/kg every 8 hours in all neonates &ge;7 days of age.</p>
<p>Neonates &le;7 days of age: AAP recommends 10 mg/kg every 12 hours in those weighing &le;2 kg and 10 mg/kg every 8 hours in those weighing &gt;2 kg.</p>
<p>Neonates 8&ndash;28 days of age: AAP recommends 10 mg/kg every 8 hours, regardless of weight.</p>
<h5>General Dosage for Infants and Children</h5>
<h6>Oral or IV</h6>
<p>Manufacturer recommends 10 mg/kg every 8 hours in infants and children through 11 years of age and 600 mg every 12 hours in adolescents &ge;12 years of age.</p>
<p>AAP recommends 10 mg/kg 3 times daily in children &lt;12 years of age and 600 mg twice daily in adolescents &ge;12 years of age.</p>
<h5>Respiratory Tract Infections</h5>
<h6>Community-acquired or Nosocomial Pneumonia</h6>
Oral or IV
<p>Children 7 days through 11 years of age: 10 mg/kg every 8 hours for 10&ndash;14 days.</p>
<p>Adolescents &ge;12 years of age: 600 mg every 12 hours for 10&ndash;14 days.</p>
<p>CAP or healthcare-associated pneumonia caused by MRSA: IDSA recommends 7&ndash;21 days of treatment.</p>
<h5>Skin and Skin Structure Infections</h5>
<h6>Uncomplicated Skin and Skin Structure Infections</h6>
Oral
<p>Children 7 days through 4 years of age: 10 mg/kg every 8 hours for 10&ndash;14 days.</p>
<p>Children 5 through 11 years of age: 10 mg/kg every 12 hours for 10&ndash;14 days.</p>
<p>Adolescents &ge;12 years of age: 600 mg every 12 hours for 10&ndash;14 days.</p>
<h6>Complicated Skin and Skin Structure Infections</h6>
Oral or IV
<p>Children 7 days through 11 years of age: 10 mg/kg every 8 hours for 10&ndash;14 days.</p>
<p>Adolescents &ge;12 years of age: 600 mg every 12 hours for 10&ndash;14 days.</p>
<h5>Vancomycin-resistant Enterococcus faecium Infections</h5>
<h6>Oral or IV</h6>
<p>Children 7 days through 11 years of age: 10 mg/kg every 8 hours for 14&ndash;28 days.</p>
<p>Adolescents &ge;12 years of age: 600 mg every 12 hours for 14&ndash;28 days.</p>
<h5>CNS Infections Caused by MRSA&dagger;</h5>
<h6>Oral or IV</h6>
<p>10 mg/kg (up to 600 mg) every 8 hours recommended by IDSA.</p>
<h4>Adults</h4>
<h5>Respiratory Tract Infections</h5>
<h6>Community-acquired or Nosocomial Pneumonia</h6>
Oral or IV
<p>600 mg every 12 hours for 10&ndash;14 days.</p>
<p>CAP or healthcare-associated pneumonia caused by MRSA: IDSA recommends 7&ndash;21 days of treatment.</p>
<h5>Skin and Skin Structure Infections</h5>
<h6>Uncomplicated Skin and Skin Structure Infections</h6>
Oral
<p>400 mg every 12 hours for 10&ndash;14 days.</p>
<p>Purulent or nonpurulent cellulitis caused by MRSA: IDSA recommends 600 mg twice daily for 5&ndash;10 days; duration depends on clinical response.</p>
<h6>Complicated Skin and Skin Structure Infections</h6>
Oral or IV
<p>600 mg every 12 hours for 10&ndash;14 days.</p>
<p>Complicated infections caused by MRSA: IDSA recommends 7&ndash;14 days of treatment; duration depends on clinical response.</p>
<h5>Vancomycin-resistant Enterococcus faecium Infections</h5>
<h6>Oral or IV</h6>
<p>600 mg every 12 hours for 14&ndash;28 days.</p>
<h5>CNS Infections Caused by MRSA&dagger;</h5>
<h6>Oral or IV</h6>
<p>600 mg every 12 hours recommended by IDSA.</p>
<h3>Special Populations</h3>
<h4>Hepatic Impairment</h4>
<p>Mild to moderate hepatic impairment (Child-Pugh class A or B): Dosage adjustments not needed.</p>
<p>Severe hepatic impairment: Pharmacokinetics not evaluated.</p>
<h4>Renal Impairment</h4>
<p>Dosage adjustments not needed. Consider that linezolid metabolites may accumulate in patients with renal impairment; clinical importance unknown. (See Renal Impairment under Cautions.)</p>
<p>Hemodialysis patients: Administer linezolid doses after dialysis session.</p>
<h4>Geriatric Patients</h4>
<p>Dosage adjustments not needed.</p>
<div class='related-links'><svg class='ddc-icon ddc-icon-info' width='22' height='22' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z' /></svg> <span><a href='/dosage/linezolid.html'>Detailed Linezolid dosage information</a></span></div>
<h2 id='cautions' class='ddc-anchor-offset'>Cautions for Linezolid</h2>
<h3>Contraindications</h3>
<ul>
<li>
<p>Known hypersensitivity to linezolid or any ingredient in the formulation.</p>
</li>
<li>
<p>Current or recent (within the last 2 weeks) treatment with drugs that inhibit MAO A or B (e.g., isocarboxazid, phenelzine). (See Specific Drugs under Interactions.)</p>
</li>
</ul>
<h3>Warnings/Precautions</h3>
<h4>Hematologic Effects</h4>
<p>Myelosuppression (anemia, leukopenia, pancytopenia, thrombocytopenia) reported.</p>
<p>Toxicity studies in adult and juvenile dogs and rats indicate myelosuppression (bone marrow hypocellularity/decreased hematopoiesis; decreased extramedullary hematopoiesis in spleen and liver; decreased levels of circulating erythrocytes, leukocytes, and platelets) and lymphoid depletion in thymus, lymph nodes, and spleen.</p>
<p>Monitor CBCs weekly during linezolid treatment, especially in those receiving the drug for &gt;2 weeks and in those who have preexisting myelosuppression, are receiving concomitant drugs associated with bone marrow suppression, or have a chronic infection that was or is being treated with concomitant anti-infective therapy.</p>
<p>Consider discontinuing linezolid if myelosuppression develops or worsens. Hematologic parameters generally have increased toward pretreatment values following discontinuance of the drug.</p>
<h4>Peripheral and Optic Neuropathy</h4>
<p>Peripheral and optic neuropathies reported in adults and children receiving linezolid, principally in those receiving the drug for &gt;28 days.  Optic neuropathy progressing to loss of vision reported when linezolid used for &gt;28 days.  Blurred vision reported in some patients who received the drug for &lt;28 days.</p>
<p>If patient experiences symptoms of visual impairment (e.g., changes in visual acuity or color vision, blurred vision, visual field defect), promptly perform an ophthalmic evaluation. Monitor visual function in all patients receiving linezolid for extended periods of time (i.e., &ge;3 months). In addition, monitor visual function in all patients reporting a new visual symptom, regardless of length of linezolid treatment.</p>
<p>If peripheral or optic neuropathy occurs, weigh potential benefits versus risks of continued linezolid treatment.</p>
<h4>Serotonin Syndrome</h4>
<p>Serotonin syndrome (including some fatalities) reported in patients receiving linezolid concomitantly with serotonergic drugs.        Signs and symptoms of serotonin syndrome include mental changes (confusion, hyperactivity, memory problems), muscle twitching, excessive sweating, shivering, shaking, diarrhea, loss of coordination, and/or fever.</p>
<p>Most reported cases occurred in patients receiving linezolid concomitantly with SSRIs or SNRIs. FDA has not concluded whether concomitant use of linezolid with other drugs with lesser degrees of serotonergic activity (e.g., tricyclic antidepressants, MAO inhibitors) is associated with a risk comparable to that reported with SSRIs or SNRIs.</p>
<p>Unless considered clinically appropriate and patients can be carefully monitored for signs and/or symptoms of serotonin syndrome or neuroleptic malignant syndrome-like (NMS-like) reactions, do not use linezolid in patients with carcinoid syndrome or in patients receiving SSRIs, tricyclic antidepressants, serotonin 5-HT<sub>1</sub> receptor agonists (triptans), meperidine, bupropion, or buspirone. (See Specific Drugs under Interactions.)</p>
<p>In cases when patient is already receiving a serotonergic antidepressant or buspirone and urgent treatment with linezolid is required (e.g., life-threatening infection caused by MRSA or vancomycin-resistant <i>E. faecium</i>) and alternatives to linezolid are not available and potential benefits of the drug outweigh risks of serotonin syndrome or NMS-like reactions, stop the serotonergic antidepressant promptly and administer linezolid.  Monitor for manifestations of serotonin syndrome or NMS-like reactions (e.g., hyperthermia, rigidity, myoclonus, autonomic instability, mental status changes that include extreme agitation progressing to delirium and coma) for 2 weeks (5 weeks if fluoxetine was taken) or until 24 hours after last linezolid dose, whichever comes first.  Also monitor for symptoms associated with discontinuance of the antidepressant.</p>
<h4>Mortality</h4>
<p>In an investigational study in seriously ill patients with intravascular catheter-related infections<a href="#unlbl-use">&dagger;</a>, mortality was higher in patients receiving linezolid than in patients receiving a comparator anti-infective (vancomycin, oxacillin, dicloxacillin); patients also could receive concomitant therapy for gram-negative infection.  There was no difference in mortality between linezolid and comparator regimens in patients with only gram-positive bacteria identified in the baseline culture; mortality was higher in linezolid-treated patients with gram-negative bacterial infections, mixed gram-positive and gram-negative infections, or no pathogen identified at baseline.  Causality not established.</p>
<p>Not approved by FDA for treatment of catheter-related bacteremia or catheter-site infections;  not approved for treatment of gram-negative bacterial infections. </p>
<h4>Monoamine Oxidase Inhibition</h4>
<p>Linezolid is a weak, nonselective, reversible inhibitor of MAO,   and potentially may interact with MAO inhibitors and adrenergic and serotonergic agents. (See Specific Drugs under Interactions.)</p>
<p>Significant pressor response reported when tyramine doses &gt;100 mg were used in adults receiving linezolid. Instruct patients to avoid large quantities of foods or beverages with high tyramine content during linezolid treatment.  Foods high in tyramine content include those that may have undergone protein changes by aging, fermentation, pickling, or smoking to improve flavor (e.g., aged cheeses, fermented or air-dried meat, sauerkraut, soy sauce, tap beer, red wine). Consider that tyramine content of any protein-rich food may be increased if stored for long periods or improperly refrigerated.</p>
<h4>Risk of Hypertension</h4>
<p>Unless monitored for potential increases in BP, do not use linezolid in patients with uncontrolled hypertension, pheochromocytoma, or thyrotoxicosis or in patients receiving direct- or indirect-acting sympathomimetic agents (e.g., pseudoephedrine), vasopressor agents (e.g., epinephrine, norepinephrine), or dopaminergic agents (e.g., dopamine, dobutamine). (See Specific Drugs under Interactions.)</p>
<h4>Lactic Acidosis</h4>
<p>Lactic acidosis, characterized by recurrent nausea and vomiting, reported.  Patients who develop recurrent nausea and vomiting, unexplained acidosis, or a low bicarbonate concentration while receiving linezolid should undergo immediate medical evaluation. </p>
<h4>Seizures</h4>
<p>Seizures reported; history of seizures or risk factors for seizures noted in some cases.</p>
<h4>Hypoglycemia</h4>
<p>Symptomatic hypoglycemia reported in patients with diabetes mellitus receiving linezolid concomitantly with insulin or oral hypoglycemic agents.</p>
<p>Although causal relationship between linezolid and hypoglycemia not established, caution patients with diabetes mellitus about potential for hypoglycemia during linezolid treatment.</p>
<p>If hypoglycemia occurs, dosage reduction of insulin or oral antidiabetic agents or discontinuance of linezolid, insulin, or oral antidiabetic agents may be necessary.</p>
<h4>Sensitivity Reactions</h4>
<p>Anaphylaxis, angioedema, and bullous skin disorders, such as those described as Stevens-Johnson syndrome, reported.</p>
<h4>Tooth Discoloration</h4>
<p>Superficial tooth discoloration and tongue discoloration reported. In cases with known outcome, tooth discoloration was removable with professional dental cleaning (manual descaling).</p>
<h4>Phenylketonuria</h4>
<p>Oral suspension contains aspartame, which is metabolized in the GI tract to provide 20 mg of phenylalanine per 5 mL of suspension. </p>
<p>Linezolid tablets do not contain aspartame  and should be used in individuals with phenylketonuria (i.e., homozygous genetic deficiency of phenylalanine hydroxylase) and other individuals who must restrict their intake of phenylalanine.</p>
<h4>Superinfection/Clostridium difficile-associated Diarrhea and Colitis (CDAD)</h4>
<p>Possible emergence and overgrowth of nonsusceptible organisms. Monitor carefully; institute appropriate therapy if superinfection occurs.</p>
<p>Treatment with anti-infectives alters normal colon flora and may permit overgrowth of <i>Clostridium difficile</i>.   </p>
<p><i>C. difficile infection (CDI) and</i><i>C. difficile</i>-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis) reported with nearly all anti-infectives, including linezolid, and may range in severity from mild diarrhea to fatal colitis.    <i>C. difficile</i> produces toxins A and B which contribute to the development of CDAD;  hypertoxin-producing strains of <i>C. difficile</i> are associated with increased morbidity and mortality since they may be refractory to anti-infectives and colectomy may be required.</p>
<p>Consider CDAD if diarrhea develops during or after therapy and manage accordingly.    Obtain careful medical history since CDAD may occur as late as &ge;2 months or longer after anti-infective therapy is discontinued.</p>
<p>If CDAD is suspected or confirmed, discontinue anti-infectives not directed against <i>C. difficile</i> whenever possible.  Initiate appropriate supportive therapy (e.g., fluid and electrolyte management, protein supplementation), anti-infective therapy directed against <i>C. difficile</i> (e.g., metronidazole, vancomycin), and surgical evaluation as clinically indicated.   </p>
<h4>Selection and Use of Anti-infectives</h4>
<p>Linezolid is indicated only for treatment of certain infections caused by certain gram-positive bacteria. The drug has no clinical activity against gram-negative bacteria and is <i>not</i> indicated for treatment of infections caused by gram-negative bacteria.</p>
<p>It is imperative that an anti-infective active against gram-negative bacteria be used concomitantly if documented or presumptive pathogens also include gram-negative bacteria. (See Uses.)</p>
<p>Safety and efficacy of linezolid given for &gt;28 days not evaluated in controlled clinical trials. (See Dosage under Dosage and Administration.)</p>
<p>To reduce development of drug-resistant bacteria and maintain effectiveness of linezolid and other antibacterials, use only for treatment of infections proven or strongly suspected to be caused by susceptible bacteria.</p>
<p>When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing. In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.</p>
<h4>Specific Populations</h4>
<h5>Pregnancy</h5>
<p>Category C.</p>
<h5>Lactation</h5>
<p>Linezolid and its metabolites are distributed into milk in rats; not known whether distributed into human milk.</p>
<p>Use with caution in nursing women.</p>
<h5>Pediatric Use</h5>
<p>Safety and efficacy for treatment of CAP, nosocomial pneumonia, complicated skin and skin structure infections, and vancomycin-resistant <i>E. faecium</i> infections in pediatric patients are supported by adequate and well-controlled studies in adults, pharmacokinetic studies in pediatric patients, and additional data from a comparator-controlled study of gram-positive infections in neonates and children through 11 years of age. Safety and efficacy for treatment of CAP in pediatric patients also is supported by evidence from an uncontrolled study in patients 8 months through 12 years of age.</p>
<p>Safety and efficacy for treatment of uncomplicated skin and skin structure infections in pediatric patients established in a comparator-controlled study in pediatric patients 5&ndash;17 years of age.</p>
<p>In children with a suboptimal response to linezolid, especially those with infections caused by pathogens with linezolid MICs of 4 mcg/mL, consider inadequate systemic exposure, site and severity of infection, and underlying medical conditions.</p>
<p>Manufacturer states not recommended for empiric treatment of CNS infections in pediatric patients. (See Distribution under Pharmacokinetics.)</p>
<h5>Geriatric Use</h5>
<p>Pharmacokinetic, safety, and efficacy profiles similar to those in younger adults.  Possibility of greater sensitivity in some older individuals cannot be ruled out.</p>
<h5>Hepatic Impairment</h5>
<p>Mild or moderate hepatic impairment (Child-Pugh class A or B): Pharmacokinetics not altered.</p>
<p>Severe hepatic impairment: Pharmacokinetics not evaluated.</p>
<h5>Renal Impairment</h5>
<p>Although clinical importance not determined, the 2 principal metabolites of linezolid may accumulate in patients with impaired renal function; amount of accumulation increases with severity of renal impairment. Weigh potential benefits against potential risks of accumulation of linezolid metabolites. (See Renal Impairment under Dosage and Administration.)</p>
<h3>Common Adverse Effects</h3>
<p>GI effects (diarrhea, nausea, vomiting, localized or generalized abdominal pain, loose stools), headache, rash, dizziness, anemia, thrombocytopenia.</p>
<h2 id='interactions' class='ddc-anchor-offset'>Interactions for Linezolid</h2>
<p>Minimally metabolized; possibly by CYP isoenzymes.</p>
<p>Does not inhibit CYP1A2, 2C9, 2C19, 2D6, 2E1, or 3A4. Does not induce CYP isoenzymes.</p>
<h3>Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes</h3>
<p>Potent inducers of hepatic enzymes: Possible reduced linezolid concentrations.</p>
<h3>Specific Drugs</h3>
<div class='responsive-table-wrap'><table>
<tr>
<th>
<p>Drug</p>
</th>
<th>
<p>Interaction</p>
</th>
<th>
<p>Comments</p>
</th>
</tr>
<tr>
<td>
<p>Aminoglycosides</p>
</td>
<td>
<p>Gentamicin: No effect on pharmacokinetics of linezolid or gentamicin  </p>
<p>Gentamicin or streptomycin: In vitro evidence of additive or indifferent antibacterial effects</p>
</td>
<td></td>
</tr>
<tr>
<td>
<p>Ampicillin</p>
</td>
<td>
<p>In vitro evidence of additive or indifferent antibacterial effects</p>
</td>
<td></td>
</tr>
<tr>
<td>
<p>Antidiabetic agents, oral</p>
</td>
<td>
<p>Potential for hypoglycemia</p>
</td>
<td>
<p>Dosage reduction of antidiabetic agent or discontinuance of linezolid or antidiabetic agent may be necessary</p>
</td>
</tr>
<tr>
<td>
<p>Aztreonam</p>
</td>
<td>
<p>No effect on pharmacokinetics of either drug  </p>
<p>In vitro evidence of additive or indifferent antibacterial effects</p>
</td>
<td></td>
</tr>
<tr>
<td>
<p>Carbamazepine</p>
</td>
<td>
<p>Possible decreased linezolid concentrations</p>
</td>
<td></td>
</tr>
<tr>
<td>
<p>Carbapenems</p>
</td>
<td>
<p>Imipenem: In vitro evidence of additive or indifferent antibacterial effects</p>
</td>
<td></td>
</tr>
<tr>
<td>
<p>Insulin</p>
</td>
<td>
<p>Potential for hypoglycemia</p>
</td>
<td>
<p>Dosage reduction of insulin or discontinuance of linezolid or insulin may be necessary</p>
</td>
</tr>
<tr>
<td>
<p>MAO inhibitors (isocarboxazid, phenelzine, selegiline, tranylcypromine)</p>
</td>
<td>
<p>Potential pharmacologic interaction</p>
<p>Increased risk of CNS toxicity, including serotonin syndrome </p>
</td>
<td>
<p>Do not use linezolid in patients who are receiving (or have received within the last 2 weeks) an MAO inhibitor (see Serotonergic Drugs under Specific Drugs)</p>
</td>
</tr>
<tr>
<td>
<p>Phenobarbital</p>
</td>
<td>
<p>Possible decreased linezolid concentrations</p>
</td>
<td></td>
</tr>
<tr>
<td>
<p>Phenytoin</p>
</td>
<td>
<p>Effect on phenytoin pharmacokinetics unlikely; possible decreased linezolid concentrations</p>
</td>
<td>
<p>Dosage adjustments not needed</p>
</td>
</tr>
<tr>
<td>
<p>Rifampin</p>
</td>
<td>
<p>Decreased peak plasma concentration and AUC of linezolid</p>
<p>In vitro evidence of additive or indifferent antibacterial effects</p>
</td>
<td>
<p>Mechanism of the interaction and clinical importance unknown</p>
</td>
</tr>
<tr>
<td>
<p>Serotonergic drugs (SSRIs, SNRIs, tricyclic antidepressants, amoxapine, bupropion, buspirone, maprotiline, meperidine, mirtazapine, nefazodone, trazodone, vilazodone)</p>
</td>
<td>
<p>Increased risk of serotonin syndrome, particularly with SSRIs and SNRIs;         unclear whether risk associated with other serotonergic drugs is comparable to that reported with SSRIs and SNRIs</p>
</td>
<td>
<p>Do not use concurrently unless considered clinically appropriate and patient can be carefully monitored for manifestations of serotonin syndrome or NMS-like reactions </p>
<p>If urgent linezolid treatment necessary (e.g., life-threatening infections caused by MRSA or vancomycin-resistant <i>E. faecium</i>), promptly discontinue the serotonergic antidepressant and administer linezolid with close monitoring (see Serotonin Syndrome under Cautions)</p>
<p>Serotonergic drug may be initiated or resumed 24 hours after last linezolid dose</p>
</td>
</tr>
<tr>
<td>
<p>Sympathomimetic agents</p>
</td>
<td>
<p>Reversible enhancement of pressor response may occur if linezolid used concomitantly with indirect-acting sympathomimetic agents (e.g., phenylpropanolamine, pseudoephedrine), vasopressor agents (e.g., epinephrine, norepinephrine), or dopaminergic agents (e.g., dopamine, dobutamine)</p>
</td>
<td>
<p>Do not use concomitantly unless patient monitored for potential BP increases</p>
<p>If adrenergic agent (e.g., dopamine, epinephrine) initiated in patient receiving linezolid, use lower initial doses of the adrenergic agent and titrate dosage to achieve desired response</p>
</td>
</tr>
<tr>
<td>
<p>Vancomycin</p>
</td>
<td>
<p>In vitro evidence of additive or indifferent antibacterial effects</p>
</td>
<td></td>
</tr>
<tr>
<td>
<p>Vitamins (ascorbic acid, vitamin E)</p>
</td>
<td>
<p>Ascorbic acid or vitamin E: Concomitant use slightly increases linezolid AUC</p>
</td>
<td>
<p>Ascorbic acid or vitamin E: Dosage adjustments not needed</p>
</td>
</tr>
<tr>
<td>
<p>Warfarin</p>
</td>
<td>
<p>No substantial effect on warfarin pharmacokinetics</p>
</td>
<td>
<p>Dosage adjustments not needed</p>
</td>
</tr>
</table></div>
<div class='related-links'><svg class='ddc-icon ddc-icon-info' width='22' height='22' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z' /></svg> <span><a href='/drug-interactions/linezolid.html'>Linezolid drug interactions</a> <span class='ddc-text-nowrap'>(more detail)</span></span></div>
<h2 id='pharmacokinetics' class='ddc-anchor-offset'>Linezolid Pharmacokinetics</h2>
<h3>Absorption</h3>
<h4>Bioavailability</h4>
<p>Rapidly and extensively absorbed after oral administration. Absolute oral bioavailability is approximately 100%. </p>
<p>Peak plasma concentrations attained within 1&ndash;2 hours following oral administration.</p>
<h4>Food</h4>
<p>Time to peak concentrations is delayed and peak concentration decreased when administered with high-fat meal; extent of absorption not affected. Not considered clinically important.</p>
<h3>Distribution</h3>
<h4>Extent</h4>
<p>Readily distributed into well-perfused tissues.</p>
<p>Adults with CNS infections: IV administration of linezolid (600 mg twice daily) resulted in steady-state mean peak CSF concentrations 36&ndash;58% of mean peak plasma concentrations;  time to peak CSF concentrations was approximately 3&ndash;4 hours after a dose.</p>
<p>Pediatric patients with ventriculoperitoneal shunts: Therapeutic concentrations not consistently achieved or maintained in CSF after single or multiple doses.</p>
<p>Linezolid and its metabolites distributed into milk in rats; not known whether distributed into human milk.</p>
<h4>Plasma Protein Binding</h4>
<p>Approximately 31%.</p>
<h3>Elimination</h3>
<h4>Metabolism</h4>
<p>Principally metabolized by oxidation of the morpholine ring to 2 inactive metabolites (metabolites A and B). Minimally metabolized; possibly mediated by CYP enzyme system.</p>
<h4>Elimination Route</h4>
<p>Approximately 65% of a dose eliminated via nonrenal clearance. At steady state, approximately 30% of dose eliminated in urine as unchanged drug, 10% as metabolite A, and 40% as metabolite B. Mean renal clearance is 40 mL/minute, suggesting net tubular reabsorption.</p>
<p>Almost no linezolid is found in feces as unchanged drug; approximately 3 and 6% of a dose is eliminated in feces as metabolites A and B, respectively.</p>
<p>Linezolid and its metabolites removed by hemodialysis. Approximately 30% of linezolid dose removed by 3-hour hemodialysis session started 3 hours after the dose.</p>
<p>Not known whether linezolid or its metabolites removed by peritoneal dialysis.  </p>
<h4>Half-life</h4>
<p>Adults: Mean elimination half-life is 4.3&ndash;6.4 hours. </p>
<p>Neonates: Mean elimination half-life is 5.6 hours in preterm neonates &lt;1 week of age, 3 hours in full-term neonates &lt;1 week of age, and 1.5 hours in neonates 1 week to 28 days of age.</p>
<p>Infants and children: Mean elimination half-life is 1.8 hours in infants &gt;28 days through 2 months of age and 2.9 hours in children 3 months through 11 years of age.</p>
<p>Adolescents 12 through 17 years of age: Mean elimination half-life is 4.1 hours.</p>
<h4>Special Populations</h4>
<p>Geriatric adults &ge;65 years of age: Pharmacokinetics similar to younger adults. </p>
<p>Pediatric patients: Clearance varies with age and there is wide intraindividual variability. Excluding neonates &lt;7 days of age, clearance is most rapid in the youngest age groups (i.e., those 7 days to 11 years of age); as children age, clearance of linezolid decreases and clearance in adolescents is similar to that observed in adults.</p>
<p>Pharmacokinetics of linezolid not affected by mild or moderate hepatic impairment (Child-Pugh class A or B); not evaluated in severe hepatic impairment.</p>
<p>Pharmacokinetics of linezolid not affected by renal impairment, but the 2 principal metabolites accumulate; amount of accumulation increases with increasing severity of renal impairment.</p>
<h2>Stability</h2>
<h3>Storage</h3>
<h4>Oral</h4>
<h5>Tablets</h5>
<p>25&deg;C. Protect from light and moisture.</p>
<h5>For Suspension</h5>
<p>25&deg;C. Protect from light and moisture. After reconstitution, store at room temperature and use within 21 days.</p>
<h4>Parenteral</h4>
<h5>Injection, for IV Infusion</h5>
<p>25&deg;C; do not freeze. Protect from light and moisture.</p>
<h3>Compatibility</h3>
<p>For information on systemic interactions resulting from concomitant use, see Interactions.</p>
<h4>Parenteral</h4>
<h5>Solution Compatibility1 HID</h5>
<div class='responsive-table-wrap'><table>
<tr>
<th>
<p>Compatible</p>
</th>
</tr>
<tr>
<td>
<p>Dextrose 5% in water</p>
</td>
</tr>
<tr>
<td>
<p>Ringer's injection, lactated</p>
</td>
</tr>
<tr>
<td>
<p>Sodium chloride 0.9%</p>
</td>
</tr>
</table></div>
<h5>Drug Compatibility</h5>
<div class='responsive-table-wrap'><table>
<caption>Admixture CompatibilityHID</caption>
<tr>
<th>
<p>Compatible</p>
</th>
</tr>
<tr>
<td>
<p>Aztreonam</p>
</td>
</tr>
<tr>
<td>
<p>Cefazolin sodium</p>
</td>
</tr>
<tr>
<td>
<p>Ceftazidime</p>
</td>
</tr>
<tr>
<td>
<p>Ciprofloxacin</p>
</td>
</tr>
<tr>
<td>
<p>Gentamicin sulfate</p>
</td>
</tr>
<tr>
<td>
<p>Levofloxacin</p>
</td>
</tr>
<tr>
<td>
<p>Tobramycin sulfate</p>
</td>
</tr>
<tr>
<th>
<p>Incompatible</p>
</th>
</tr>
<tr>
<td>
<p>Ceftriaxone sodium</p>
</td>
</tr>
<tr>
<td>
<p>Co-trimoxazole</p>
</td>
</tr>
<tr>
<td>
<p>Erythromycin lactobionate</p>
</td>
</tr>
</table></div>
<div class='responsive-table-wrap'><table>
<caption>Y-Site CompatibilityHID</caption>
<tr>
<th>
<p>Compatible</p>
</th>
</tr>
<tr>
<td>
<p>Acyclovir sodium</p>
</td>
</tr>
<tr>
<td>
<p>Alfentanil HCl</p>
</td>
</tr>
<tr>
<td>
<p>Amikacin sulfate</p>
</td>
</tr>
<tr>
<td>
<p>Aminophylline</p>
</td>
</tr>
<tr>
<td>
<p>Ampicillin sodium</p>
</td>
</tr>
<tr>
<td>
<p>Ampicillin sodium&ndash;sulbactam sodium</p>
</td>
</tr>
<tr>
<td>
<p>Anidulafungin</p>
</td>
</tr>
<tr>
<td>
<p>Aztreonam</p>
</td>
</tr>
<tr>
<td>
<p>Buprenorphine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Butorphanol tartrate</p>
</td>
</tr>
<tr>
<td>
<p>Calcium gluconate</p>
</td>
</tr>
<tr>
<td>
<p>Carboplatin</p>
</td>
</tr>
<tr>
<td>
<p>Caspofungin acetate</p>
</td>
</tr>
<tr>
<td>
<p>Cefazolin sodium</p>
</td>
</tr>
<tr>
<td>
<p>Cefotetan disodium</p>
</td>
</tr>
<tr>
<td>
<p>Cefoxitin sodium</p>
</td>
</tr>
<tr>
<td>
<p>Ceftazidime</p>
</td>
</tr>
<tr>
<td>
<p>Ceftriaxone sodium</p>
</td>
</tr>
<tr>
<td>
<p>Cefuroxime sodium</p>
</td>
</tr>
<tr>
<td>
<p>Ciprofloxacin</p>
</td>
</tr>
<tr>
<td>
<p>Cisatracurium besylate</p>
</td>
</tr>
<tr>
<td>
<p>Cisplatin</p>
</td>
</tr>
<tr>
<td>
<p>Clindamycin phosphate</p>
</td>
</tr>
<tr>
<td>
<p>Cyclophosphamide</p>
</td>
</tr>
<tr>
<td>
<p>Cyclosporine</p>
</td>
</tr>
<tr>
<td>
<p>Cytarabine</p>
</td>
</tr>
<tr>
<td>
<p>Dexamethasone sodium phosphate</p>
</td>
</tr>
<tr>
<td>
<p>Dexmedetomidine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Digoxin</p>
</td>
</tr>
<tr>
<td>
<p>Diphenhydramine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Dobutamine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Dopamine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Doripenem</p>
</td>
</tr>
<tr>
<td>
<p>Doxorubicin HCl</p>
</td>
</tr>
<tr>
<td>
<p>Doxycycline hyclate</p>
</td>
</tr>
<tr>
<td>
<p>Droperidol</p>
</td>
</tr>
<tr>
<td>
<p>Enalaprilat</p>
</td>
</tr>
<tr>
<td>
<p>Esmolol HCl</p>
</td>
</tr>
<tr>
<td>
<p>Etoposide phosphate</p>
</td>
</tr>
<tr>
<td>
<p>Famotidine</p>
</td>
</tr>
<tr>
<td>
<p>Fenoldopam mesylate</p>
</td>
</tr>
<tr>
<td>
<p>Fentanyl citrate</p>
</td>
</tr>
<tr>
<td>
<p>Fluconazole</p>
</td>
</tr>
<tr>
<td>
<p>Fluorouracil</p>
</td>
</tr>
<tr>
<td>
<p>Furosemide</p>
</td>
</tr>
<tr>
<td>
<p>Ganciclovir sodium</p>
</td>
</tr>
<tr>
<td>
<p>Gemcitabine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Gentamicin sulfate</p>
</td>
</tr>
<tr>
<td>
<p>Granisetron HCl</p>
</td>
</tr>
<tr>
<td>
<p>Haloperidol lactate</p>
</td>
</tr>
<tr>
<td>
<p>Heparin sodium</p>
</td>
</tr>
<tr>
<td>
<p>Hydrocortisone sodium succinate</p>
</td>
</tr>
<tr>
<td>
<p>Hydromorphone HCl</p>
</td>
</tr>
<tr>
<td>
<p>Hydroxyzine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Ifosfamide</p>
</td>
</tr>
<tr>
<td>
<p>Imipenem&ndash;cilastatin sodium</p>
</td>
</tr>
<tr>
<td>
<p>Labetalol HCl</p>
</td>
</tr>
<tr>
<td>
<p>Leucovorin calcium</p>
</td>
</tr>
<tr>
<td>
<p>Levofloxacin</p>
</td>
</tr>
<tr>
<td>
<p>Lidocaine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Lorazepam</p>
</td>
</tr>
<tr>
<td>
<p>Magnesium sulfate</p>
</td>
</tr>
<tr>
<td>
<p>Mannitol</p>
</td>
</tr>
<tr>
<td>
<p>Meperidine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Meropenem</p>
</td>
</tr>
<tr>
<td>
<p>Mesna</p>
</td>
</tr>
<tr>
<td>
<p>Methotrexate sodium</p>
</td>
</tr>
<tr>
<td>
<p>Methylprednisolone sodium succinate</p>
</td>
</tr>
<tr>
<td>
<p>Metoclopramide HCl</p>
</td>
</tr>
<tr>
<td>
<p>Metronidazole</p>
</td>
</tr>
<tr>
<td>
<p>Midazolam HCl</p>
</td>
</tr>
<tr>
<td>
<p>Mitoxantrone HCl</p>
</td>
</tr>
<tr>
<td>
<p>Morphine sulfate</p>
</td>
</tr>
<tr>
<td>
<p>Nalbuphine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Naloxone HCl</p>
</td>
</tr>
<tr>
<td>
<p>Nicardipine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Nitroglycerin</p>
</td>
</tr>
<tr>
<td>
<p>Ondansetron HCl</p>
</td>
</tr>
<tr>
<td>
<p>Paclitaxel</p>
</td>
</tr>
<tr>
<td>
<p>Pentobarbital sodium</p>
</td>
</tr>
<tr>
<td>
<p>Phenobarbital sodium</p>
</td>
</tr>
<tr>
<td>
<p>Piperacillin sodium&ndash;tazobactam sodium</p>
</td>
</tr>
<tr>
<td>
<p>Potassium chloride</p>
</td>
</tr>
<tr>
<td>
<p>Prochlorperazine edisylate</p>
</td>
</tr>
<tr>
<td>
<p>Promethazine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Propranolol HCl</p>
</td>
</tr>
<tr>
<td>
<p>Ranitidine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Remifentanil HCl</p>
</td>
</tr>
<tr>
<td>
<p>Sodium bicarbonate</p>
</td>
</tr>
<tr>
<td>
<p>Sufentanil citrate</p>
</td>
</tr>
<tr>
<td>
<p>Theophylline</p>
</td>
</tr>
<tr>
<td>
<p>Tigecycline</p>
</td>
</tr>
<tr>
<td>
<p>Tobramycin sulfate</p>
</td>
</tr>
<tr>
<td>
<p>Vancomycin HCl</p>
</td>
</tr>
<tr>
<td>
<p>Vasopressin</p>
</td>
</tr>
<tr>
<td>
<p>Vecuronium bromide</p>
</td>
</tr>
<tr>
<td>
<p>Verapamil HCl</p>
</td>
</tr>
<tr>
<td>
<p>Vincristine sulfate</p>
</td>
</tr>
<tr>
<td>
<p>Zidovudine</p>
</td>
</tr>
<tr>
<th>
<p>Incompatible</p>
</th>
</tr>
<tr>
<td>
<p>Amphotericin B</p>
</td>
</tr>
<tr>
<td>
<p>Chlorpromazine HCl</p>
</td>
</tr>
<tr>
<td>
<p>Diazepam</p>
</td>
</tr>
<tr>
<td>
<p>Pentamidine isethionate</p>
</td>
</tr>
<tr>
<td>
<p>Phenytoin sodium</p>
</td>
</tr>
</table></div>
<h2>Actions and Spectrum</h2>
<ul>
<li>
<p>Oxazolidinone anti-infective agent.    </p>
</li>
<li>
<p>Binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents formation of a functional 70S initiation complex.   </p>
</li>
<li>
<p>Bacteriostatic in vitro against susceptible enterococci and staphylococci; bactericidal against susceptible streptococci. </p>
</li>
<li>
<p>Active in vitro against <i>Staphylococcus aureus</i> (including methicillin-resistant <i>S. aureus</i> [MRSA; also known as oxacillin-resistant <i>S. aureus</i> or ORSA]),      <i>Streptococcus agalactiae</i> (group B streptococci, GBS),   <i>S. pneumoniae</i>,   and <i>S. pyogenes</i> (group A &beta;-hemolytic streptococci, GAS).   Although clinical importance unknown, also active in vitro against <i>S. epidermidis</i> (including methicillin-resistant [oxacillin-resistant] strains),     <i>S. haemolyticus</i>,   viridans group streptococci,  group G streptococci, <i>Corynebacterium</i>, and <i>Pasteurella multocida</i>.  </p>
</li>
<li>
<p>Active in vitro against vancomycin-resistant <i>Enterococcus faecium</i>.     Although clinical importance unknown, also active in vitro against <i>E. faecium</i> (vancomycin-susceptible strains) and <i>E. faecalis</i> (including vancomycin-resistant strains).   </p>
</li>
<li>
<p>Active in vitro against <i>Mycobacterium tuberculosis</i>,    including some multiple-drug resistant (MDR) and extensively drug-resistant (XDR) strains.  Also has activity in vitro against some strains of <i>M. chelonaei</i>, <i>M. fortuitum</i>, <i>M. gilvum</i>, <i>M. gordonae</i>, <i>M. kansasii</i>, <i>M. mucogenicum</i>, and <i>M. simiae</i>.</p>
</li>
<li>
<p>Resistance to linezolid has been produced in vitro by serial passage of MRSA or enterococci (i.e., <i>E. faecalis</i>, <i>E. faecium</i>) in the presence of increasing concentrations of the drug   and has emerged in patients receiving the drug for treatment of infections caused by MRSA  or enterococci. </p>
</li>
<li>
<p>Linezolid resistance generally associated with point mutations in 23S rRNA.  However, linezolid resistance in staphylococci mediated by the chloramphenicol-florfenicol (<i>cfr</i>) gene located on a plasmid has been reported and such resistance is transferable between staphylococci.</p>
</li>
<li>
<p>Cross-resistance between linezolid and other oxazolidinones (e.g., tedizolid) reported.   Bacteria resistant to linezolid because of mutations in chromosomal genes encoding the 23S rRNA or ribosomal proteins (L3 and L4) generally cross-resistant to other oxazolidinones (e.g., tedizolid) and vice versa.   In vitro data indicate presence of <i>cfr</i> gene in <i>S. aureus</i> that results in resistance to linezolid does not necessarily result in cross-resistance to tedizolid in the absence of chromosomal mutations.   </p>
</li>
<li>
<p>Cross-resistance between linezolid and non-oxazolidinone anti-infectives unlikely.  </p>
</li>
</ul>
<h2 id='patient-advice' class='ddc-anchor-offset'>Advice to Patients</h2>
<ul>
<li>
<p>Advise patients that antibacterials (including linezolid) should only be used to treat bacterial infections and not used to treat viral infections (e.g., the common cold).</p>
</li>
<li>
<p>Importance of completing full course of therapy, even if feeling better after a few days.</p>
</li>
<li>
<p>Advise patients that skipping doses or not completing the full course of therapy may decrease effectiveness and increase the likelihood that bacteria will develop resistance and will not be treatable with linezolid or other antibacterials in the future.</p>
</li>
<li>
<p>Advise patients that linezolid may be taken orally without regard to meals.</p>
</li>
<li>
<p>If using the oral suspension, importance of not shaking the bottle vigorously and gently inverting the bottle 3&ndash;5 times to resuspend the drug prior to administration of each dose.</p>
</li>
<li>
<p>Advise patients of the potential risk of serotonin syndrome, particularly if linezolid is used concomitantly with MAO inhibitors, SSRIs, SNRIs, tricyclic antidepressants, or other serotonergic drugs. Importance of immediately contacting clinician if signs and symptoms of serotonin syndrome develop (e.g., confusion, hyperactivity, memory problems, muscle twitching, excessive sweating, shivering, shaking, diarrhea, loss of coordination, fever). Importance of not discontinuing serotonergic drugs without first consulting clinician.</p>
</li>
<li>
<p>Advise patients, particularly those with diabetes mellitus, that hypoglycemic reactions (diaphoresis and tremulousness) and low blood glucose concentrations may occur during linezolid treatment. Importance of contacting a clinician to obtain proper treatment if such reactions occur.</p>
</li>
<li>
<p>Importance of avoiding large quantities of foods or beverages with high tyramine content during linezolid treatment; this includes foods or beverages that have been aged, fermented, pickled, or smoked to improve flavor (e.g., aged cheeses, fermented or air-dried meats, sauerkraut, soy sauce, tap beer, red wine). Consider that tyramine content of any protein-rich food may be increased if stored for long periods or improperly refrigerated.</p>
</li>
<li>
<p>Advise individuals with phenylketonuria that the oral suspension contains aspartame, which is metabolized in the GI tract to provide 20 mg of phenylalanine per 5 mL of suspension.</p>
</li>
<li>
<p>Importance of notifying clinician of any history of hypertension or seizures.</p>
</li>
<li>
<p>Importance of notifying clinician if any change in vision occurs.</p>
</li>
<li>
<p>Advise patients that diarrhea is a common problem caused by anti-infectives and usually ends when the drug is discontinued. Importance of contacting a clinician if watery and bloody stools (with or without stomach cramps and fever) occur during or as late as 2 months or longer after the last dose.</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy including prescription drugs (e.g., antidepressants) and OTC drugs (e.g., pseudoephedrine), as well as any concomitant illnesses.</p>
</li>
<li>
<p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.</p>
</li>
<li>
<p>Importance of advising patients of other important precautionary information. (See Cautions.)</p>
</li>
</ul>
<h2 id='preparations' class='ddc-anchor-offset'>Preparations</h2>
<p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p>
<p><i>Please refer to the <a href="https://www.ashp.org/Drug-Shortages">ASHP Drug Shortages Resource Center</a> for information on shortages of one or more of these preparations.</i></p>
<p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p>
<div class='responsive-table-wrap'><table>
<caption>Linezolid</caption>
<tr>
<th>
<p>Routes</p>
</th>
<th>
<p>Dosage Forms</p>
</th>
<th>
<p>Strengths</p>
</th>
<th>
<p>Brand Names</p>
</th>
<th>
<p>Manufacturer</p>
</th>
</tr>
<tr>
<td>
<p>Oral</p>
</td>
<td>
<p>For suspension</p>
</td>
<td>
<p>100 mg/5 mL*</p>
</td>
<td>
<p>Linezolid for Suspension</p>
</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>
<p>Zyvox<sup></sup></p>
</td>
<td>
<p>Pfizer</p>
</td>
</tr>
<tr>
<td></td>
<td>
<p>Tablets, film-coated</p>
</td>
<td>
<p>600 mg*</p>
</td>
<td>
<p>Linezolid Tablets</p>
</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>
<p>Zyvox<sup></sup></p>
</td>
<td>
<p>Pfizer</p>
</td>
</tr>
<tr>
<td>
<p>Parenteral</p>
</td>
<td>
<p>Injection, for IV infusion</p>
</td>
<td>
<p>2 mg/mL (200, 400, and 600 mg) in sterile isotonic solution*</p>
</td>
<td>
<p>Linezolid Injection</p>
</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>
<p>Zyvox<sup></sup> Injection (in flexible containers)</p>
</td>
<td>
<p>Pfizer</p>
</td>
</tr>
</table></div>
<div class="disclaimer no-ad">
<p>AHFS<sup></sup> DI Essentials&trade;. &copy; Copyright 2021, Selected Revisions March 10, 2016. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p>
<p><a name="unlbl-use" id="unlbl-use"></a>&dagger; Use is not currently included in the labeling approved by the US Food and Drug Administration.</p>
</div>
<p class="ddc-mgt-2"><a href="?references=1">Show article references</a></p>
<div id='moreResources' class='more-resources'>
<h2>More about linezolid</h2>
<ul class='more-resources-list more-resources-list-general'>
<li><a href='/sfx/linezolid-side-effects.html'>Side Effects</a></li>
<li><a href='/pregnancy/linezolid.html'>During Pregnancy</a> or 
<a href='/breastfeeding/linezolid.html'>Breastfeeding</a></li>
<li><a href='/dosage/linezolid.html' data-action='drug-dosage-disambiguation' data-ddc_id='1472' data-brand_id='0'>Dosage Information</a></li>
<li><a href='/linezolid-images.html'>Drug Images</a></li>
<li><a href='/drug-interactions/linezolid.html'>Drug Interactions</a></li>
<li><a href='/price-guide/linezolid'>Pricing &amp; Coupons</a></li>
<li><a href='/mtm_esp/linezolid-oral-injection.html'>En Espa&ntilde;ol</a></li>
<li><a href='/comments/linezolid/'>28 Reviews</a></li>
<li><a href='/drug-class/oxazolidinone-antibiotics.html'>Drug class: oxazolidinone antibiotics</a></li>
</ul>
<h3>Consumer resources</h3>
<ul class='more-resources-list more-resources-list-consumer'>
<li><a href='/mtm/linezolid-oral-injection.html'>Patient Information</a></li>
<li data-more-config-id='list-data-resources-consumer'><a href='#' class='more-resources-more-toggle' data-more-toggle rel='nofollow'>... +5 more</a></li>
</ul>
<h3>Professional resources</h3>
<ul class='more-resources-list more-resources-list-professional'>
<li><a href='/ppa/linezolid.html'>Prescribing Information</a></li>
<li><a href='/pro/linezolid-injection.html'>Linezolid Injection <span>(FDA)</span></a></li>
<li><a href='/pro/linezolid-oral-suspension.html'>Linezolid Oral Suspension <span>(FDA)</span></a></li>
<li><a href='/pro/linezolid-tablets.html'>Linezolid Tablets <span>(FDA)</span></a></li>
</ul>
<dl class='more-resources-other-brands more-resources-other-brands-professional'><dt>Other brands</dt><dd><a href='/pro/zyvox.html'>Zyvox</a></dd></dl>
<h3>Related treatment guides</h3>
<ul class='more-resources-list more-resources-list-conditions'>
<li><a href='/condition/bacterial-infection.html' data-send-data='/js/async/drug-condition-log.php' data-type='drug-condition' data-ddc_id='1472' data-brand_name_id='0' data-condition_id='954'>Bacterial Infection</a></li>
<li><a href='/condition/skin-and-structure-infection.html' data-send-data='/js/async/drug-condition-log.php' data-type='drug-condition' data-ddc_id='1472' data-brand_name_id='0' data-condition_id='974'>Skin and Structure Infection</a></li>
<li><a href='/cg/bacteremia.html' data-send-data='/js/async/drug-condition-log.php' data-type='drug-condition' data-ddc_id='1472' data-brand_name_id='0' data-condition_id='523'>Bacteremia</a></li>
<li><a href='/condition/methicillin-resistant-staphylococcus-aureus-mrsa-infection.html' data-send-data='/js/async/drug-condition-log.php' data-type='drug-condition' data-ddc_id='1472' data-brand_name_id='0' data-condition_id='10139'>Methicillin-Resistant Staphylococcus Aureus Infection</a></li>
<li><a href='/condition/nosocomial-pneumonia.html' data-send-data='/js/async/drug-condition-log.php' data-type='drug-condition' data-ddc_id='1472' data-brand_name_id='0' data-condition_id='1254'>Nosocomial Pneumonia</a></li>
<li><a href='/health-guide/pneumonia.html' data-send-data='/js/async/drug-condition-log.php' data-type='drug-condition' data-ddc_id='1472' data-brand_name_id='0' data-condition_id='802'>Pneumonia</a></li>
</ul>
</div>
<p class='ddc-disclaimer-link'><a href='/support/disclaimer-pro.html'>Medical Disclaimer</a></p>

</div>
<!-- google_ad_section_end -->

</div>


<div id='sidebar' class='ddc-clearfix'>
<div class='ddc-status-info'>
	<h3 class='ddc-status-info-title'>Drug Status</h3>
	<div class="ddc-box">
		<div class="ddc-accordion" role="presentation">

			
		<div class='ddc-accordion-section'>
			<div class='ddc-accordion-header ddc-mg-0'  data-static='true'>
				<h4 class='ddc-accordion-heading'>Availability
					<span class='ddc-accordion-summary ddc-display-block ddc-mg-0'>Prescription only</span>
					<span class='ddc-status-icon drugInfoRx1'>Rx</span>
					</h4>
			</div>
			
		</div>
		
		<div class='ddc-accordion-section'>
			<div class='ddc-accordion-header ddc-mg-0'  data-static='true'>
				<h4 class='ddc-accordion-heading'><a href='/pregnancy/linezolid.html'>Pregnancy &amp; Lactation
					<span class='ddc-accordion-summary ddc-display-block ddc-mg-0'>Risk data available</span>
					<span class='ddc-status-icon drugInfoPregMultiple'><svg class='ddc-icon ddc-icon-pregnancy' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M10.62 7.03c.38-1.4 2.43-2.17 3.3-1.27.2.2.33.5.48.98l.11.36.12.42.06.23.29 1.13.09.34.02.08c.08.17.48.42 1.19.69l.98.34.26.1.3.14a2.7 2.7 0 011.42 2.99c-.2 1.2-.9 2.25-2.24 3.68a8.56 8.56 0 01-5.62 2.44c-2.35.17-4.48-1.02-5.23-2.63a5.89 5.89 0 01-.24-.6l-.11-.35-.12-.42-.26-.94-.09-.32-.08-.27-.08-.2-.07-.16a.57.57 0 00-.08-.14H5l-.1.01-.15.02-.62.13c-.35.06-.56.07-.83 0-.87-.18-1.3-.67-1.5-1.45a2.28 2.28 0 011-2.36l.16-.1.1-.06.18-.1.22-.1.24-.11.45-.18.36-.14.93-.34c1.67-.6 2.7-.28 3.44.85a3 3 0 01.51 1.27l.07.46.04.18c.07.33.37.5.8.5.2 0 .77-.24 1.14-.44l.07-.05-.1-.15-.17-.27-.07-.12a1 1 0 01-.06-.19l-.02-.08-.24-.9-.1-.48c-.06-.26-.1-.5-.14-.74-.08-.59-.1-1.1-.02-1.54zm2.24-.14h-.02c-.09 0-.19.03-.28.07-.28.1-.46.29-.5.47-.04.26-.03.63.03 1.07.05.3.11.63.2.98l.27 1.05c0-.01 0-.01 0 0l.17.23.17.26c.08.14.14.26.19.4a1 1 0 01-.17 1.01c-.42.5-1.88 1.2-2.62 1.2-1.06 0-2.03-.56-2.27-1.7a8.8 8.8 0 01-.08-.41l-.07-.43-.02-.1a1.6 1.6 0 00-.23-.44c-.36-.54-.65-.63-1.69-.26l-.66.24-.66.25-.37.15-.2.08-.16.09-.14.08-.2.12c-.2.14-.34.51-.3.69.08.27.1.3.36.36h.16l.08-.02.54-.1c.78-.15 1.26-.1 1.73.4.26.28.43.63.62 1.26l.12.41.31 1.16.1.33.1.28.04.13.1.22c.48 1.03 2.02 1.9 3.76 1.77a7.08 7.08 0 004.63-1.97c1.15-1.23 1.72-2.1 1.86-2.92.12-.68-.12-1.13-.64-1.4a.6.6 0 00-.04-.03l-.16-.06-.35-.13-.8-.28-.24-.1c-.96-.37-1.55-.78-1.82-1.43l-.03-.07-.05-.17-.06-.22-.44-1.7-.1-.35-.1-.27-.07-.2zM19 3.25a3.25 3.25 0 110 6.5 3.25 3.25 0 010-6.5zm0 1.5a1.75 1.75 0 100 3.5 1.75 1.75 0 000-3.5z' /></svg></span>
					</a></h4>
			</div>
			
		</div>
		
		<div class='ddc-accordion-section'>
			<div class='ddc-accordion-header ddc-mg-0' aria-expanded='false' id='accordion-heading-2' role='button' tabindex='0' aria-controls='accordion-content-2' data-type='csa' data-box-info-module='drug' data-id='N' data-ddc_id='0' data-brand_name_id='0'>
				<h4 class='ddc-accordion-heading'>CSA Schedule*
					<span class='ddc-accordion-summary ddc-display-block ddc-mg-0'>Not a controlled drug</span>
					<span class='ddc-status-icon drugInfoCSAN'>N/A</span>
					<svg class='ddc-icon ddc-icon-accordion-expand' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z' /></svg></h4>
			</div>
			
<div class='ddc-status-info-content ddc-accordion-content ddc-text-wordbreak' id='accordion-content-2' aria-labelledby='accordion-heading-2'>
	<div class='ddc-text-color-secondary ddc-text-size-small' aria-live='polite'>
	  <p>Loading...</p>
	</div>
</div>
		</div>
		
		<div class='ddc-accordion-section'>
			<div class='ddc-accordion-header ddc-mg-0' aria-expanded='false' id='accordion-heading-3' role='button' tabindex='0' aria-controls='accordion-content-3' data-type='approval' data-box-info-module='drug' data-id='/monograph/linezolid.html' data-ddc_id='1472' data-brand_name_id='0'>
				<h4 class='ddc-accordion-heading'>Approval History
					<span class='ddc-accordion-summary ddc-display-block ddc-mg-0'>Drug history at FDA</span>
					<span class='ddc-status-icon drugInfoDateCal'><svg class='ddc-icon ddc-icon-history' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M8.75 2.25v1h6.5v-1h1.5v1H19c.92 0 1.67.7 1.74 1.6l.01.15v14c0 .97-.78 1.75-1.75 1.75H5c-.97 0-1.75-.78-1.75-1.75V5c0-.97.78-1.75 1.75-1.75h2.25v-1h1.5zm10.5 6.5H4.75V19c0 .12.08.22.2.24l.05.01h14c.14 0 .25-.11.25-.25V8.75zm-12-4H5a.25.25 0 00-.25.25v2.25h14.5V5a.25.25 0 00-.2-.24L19 4.75h-2.25v1h-1.5v-1h-6.5v1h-1.5v-1z' /></svg></span>
					<svg class='ddc-icon ddc-icon-accordion-expand' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z' /></svg></h4>
			</div>
			
<div class='ddc-status-info-content ddc-accordion-content ddc-text-wordbreak' id='accordion-content-3' aria-labelledby='accordion-heading-3'>
	<div class='ddc-text-color-secondary ddc-text-size-small' aria-live='polite'>
	  <p>Loading...</p>
	</div>
</div>
		</div>
				</div>
	</div>
</div>
	<div class="sideBox sideBoxRelatedDrugs">
	<div class="sideBoxHead">
		<div class="sideBoxTitle">Related Drugs</div>
	</div>
	<div class="sideBoxContent">
<p><a href="/amoxicillin.html">amoxicillin</a>, <a href="/doxycycline.html">doxycycline</a>, <a href="/ciprofloxacin.html">ciprofloxacin</a>, <a href="/metronidazole.html">metronidazole</a>, <a href="/azithromycin.html">azithromycin</a>, <a href="/cephalexin.html">cephalexin</a>, <a href="/clindamycin.html">clindamycin</a>, <a href="/augmentin.html">Augmentin</a>, <a href="/mtm/levofloxacin.html">levofloxacin</a>, <a href="/mtm/ceftriaxone-injection.html">ceftriaxone</a></p>	</div>
</div>
<div class='sideBox sideBoxUserReviews'>
	<div class='sideBoxContent ddc-clearfix'>
		<div class='sideBoxTitle'>User Reviews &amp; Ratings</div>
		<div class='ddc-rating-summary'>

<div><b>8.6</b><span class='ddc-text-color-secondary'> / 10</span></div>
<div class='ddc-rating-bar'><span style='width: 86.4%;'></span></div>
<em><a href='/comments/linezolid/'>28 Reviews</a></em>
		</div>
	</div>
</div>
<div class="sideBox sideBoxDrugImage">
	<div class="sideBoxHead">
		<div class="sideBoxTitle">Images</div>
	</div>
	<div class="sideBoxContent">
		<div id='drug-imprint-primary' class="drugImage">
			<div class="drugImageHolder">
				<a href="/imprints/lzd-600-23349.html" title="View larger image">
					<img alt="Pill Imprint LZD 600 (Linezolid 600 mg)" src='/img/pixel.gif' width='300' height='225' data-lazy-load data-src='https://www.drugs.com/images/pills/nlm/00093-8244-34_NLMIMAGE10_FC43FE6F.jpg'>
					<noscript><img alt="Pill Imprint LZD 600 (Linezolid 600 mg)" src='https://www.drugs.com/images/pills/nlm/00093-8244-34_NLMIMAGE10_FC43FE6F.jpg'></noscript>
				</a>
			</div>
			<div class="drugImageText">
				Linezolid systemic 600 mg (LZD 600)			</div>
		</div>

		<nav class='drugImageNav' aria-label="Browse pill images">
<a href='#' role='button' data-drug-imprint-image data-url='/imprints/lzd-600-23349.html' data-label='Linezolid systemic 600 mg (LZD 600)'><img alt='Linezolid systemic 600 mg (LZD 600)' src='/img/pixel.gif' width='100' height='75' data-lazy-load data-src='https://www.drugs.com/images/pills/nlm/00093-8244-34_NLMIMAGE10_FC43FE6F.jpg'></a>
<a href='#' role='button' data-drug-imprint-image data-url='/imprints/mylan-l77-24036.html' data-label='Linezolid systemic 600 mg (MYLAN L77)'><img alt='Linezolid systemic 600 mg (MYLAN L77)' src='/img/pixel.gif' width='100' height='75' data-lazy-load data-src='https://www.drugs.com/images/pills/custom/pill24036-1/linezolid.jpeg'></a>
<a class='more' href='/linezolid-images.html' role='button'>View all images</a>
		</nav>
	</div>
</div>
	<div id='sideBoxStackedAdWrap-1' class='sideBoxStackedAdWrap'>
		<div id='sideBoxStackedAd-1' class='sideBox sideBoxFixedAd300 sideBoxStackedAd'>
			<div id='drugs-drugs-2' class='display-ad display-ad-300x600'>
<script>
var ehs_ad_called = ++ehs_ad_called || 1;
</script>
</div>
<script src='//ads.ehealthcaresolutions.com/a/?adid=drugs-drugs-2&slotid=2&url=www.drugs.com%2Fmonograph%2Flinezolid.html&size=300x250,300x600&vpos=t&hpos=r&site=ehs.pro.drugs.drugs&drg=linezolid&drc=oxazolidinone_antibiotics&dra=1' defer></script>
		</div>
	</div>
	</div>

</div>
</main>

<footer id='footer' class='footer ddc-clearfix'>
	<section class="footer-feature">
		<div class="container">
			<div class="promo-content" data-lazy-load data-background-image='/img/apps/promo-uberapp.png'>
				<h2 class='ddc-mgt-0 ddc-text-weight-bold'>Drugs.com <span>Mobile Apps</span></h2>
				<p>The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.</p>
				<a href="/apps/" class="ddc-btn" onclick="ga('send', { hitType: 'event', eventCategory: 'App Promo', eventAction: 'Footer', eventLabel: 'Explore Apps' });">Explore Apps</a>
			</div>
		</div>
	</section>

	<div class="container">
		<div class="footer-sections">
			<div class='footer-logomark' data-lazy-load data-background-image='/img/logo/drugscom-logo.png'></div>

			<div class="footer-content-links">
				<section class="footer-section">
					<h2 class='ddc-mgt-0'>Support</h2>
					<ul class='ddc-list-unstyled ddc-mg-0'>
						<li><a href='/support/'>Help Center</a></li>
						<li><a href='/sitemap.html'>Sitemap</a></li>
						<li><a href="/support/contact.html">Contact Us</a></li>
					</ul>
				</section>

				<section class="footer-section">
					<h2 class='ddc-mgt-0'>About</h2>
					<ul class='ddc-list-unstyled ddc-mg-0'>
						<li><a href="/support/about.html">About Drugs.com</a></li>
						<li><a href="/support/advertising.html">Advertising Policy</a></li>
						<li><a href="/support/citations.html">Attribution &amp; Citations</a></li>
					</ul>
				</section>

				<section class="footer-section ddc-mg-0">
					<h2 class='ddc-mgt-0'>Terms &amp; Privacy</h2>
					<ul class='ddc-list-unstyled ddc-mg-0'>
						<li><a href='/support/editorial_policy.html'>Editorial Policy</a></li>
						<li><a href='/support/privacy.html'>Privacy Policy</a>
						</li>
						<li><a href='/support/terms.html'>Terms of Use</a></li>
					</ul>
				</section>

				<div class="footer-section footer-social">
					<ul class="footer-social-list ddc-list-inline ddc-mgt-0 ddc-mgb-1">
						<li>
							<a href="https://www.facebook.com/Drugscom" target='_blank' rel='noopener' class="ddc-share-icon ddc-share-icon-facebook">
								<span class='ddc-share-icon-label'>Follow Drugs.com on Facebook</span> <svg class='ddc-icon ddc-icon-facebook' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M14 6.54c-2.06 0-3.4 1.25-3.4 3.52v2H8.3v2.61h2.3V21A9.04 9.04 0 013 12.05C3 7.05 7.03 3 12 3s9 4.05 9 9.05c0 4.53-3.3 8.27-7.6 8.95v-6.33h2.1l.4-2.62h-2.5v-1.7c0-.7.35-1.4 1.47-1.4h1.14V6.7s-1.03-.17-2.02-.17z' /></svg>							</a>
						</li>
						<li>
							<a href="https://twitter.com/drugscom" target='_blank' rel='noopener' class="ddc-share-icon ddc-share-icon-twitter">
								<span class='ddc-share-icon-label'>Follow Drugs.com on Twitter</span> <svg class='ddc-icon ddc-icon-twitter' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M8.66 19.63a10.44 10.44 0 0010.5-10.5v-.5A7.7 7.7 0 0021 6.74c-.67.3-1.39.5-2.12.58a3.73 3.73 0 001.64-2.04c-.72.43-1.52.74-2.34.9a3.7 3.7 0 00-6.3 3.36 10.46 10.46 0 01-7.61-3.85 3.69 3.69 0 001.14 4.9 3.66 3.66 0 01-1.63-.45v.04a3.7 3.7 0 002.9 3.64 3.7 3.7 0 01-1.63.06 3.69 3.69 0 003.42 2.53 7.4 7.4 0 01-4.6 1.64 8 8 0 01-.87-.07 10.45 10.45 0 005.66 1.63' /></svg>							</a>
						</li>
						<li>
							<a href="https://www.pinterest.com/drugscom/" target='_blank' rel='noopener' class="ddc-share-icon ddc-share-icon-pinterest">
								<span class='ddc-share-icon-label'>Follow Drugs.com on Pinterest</span> <svg class='ddc-icon ddc-icon-pinterest' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M11.97 3a9 9 0 00-3.29 17.36 8.48 8.48 0 010-2.57l1.06-4.5c-.16-.41-.25-.85-.24-1.29 0-1.25.73-2.19 1.63-2.19a1.14 1.14 0 011.14 1.29c0 .77-.49 1.93-.75 3a1.28 1.28 0 001.35 1.62c1.6 0 2.83-1.69 2.83-4.12a3.55 3.55 0 00-3.77-3.66 3.92 3.92 0 00-4.08 3.9c0 .74.22 1.46.65 2.06.06.07.09.16.06.25l-.25 1.03c-.02.12-.13.2-.3.12-1.13-.53-1.83-2.17-1.83-3.5 0-2.83 2.07-5.44 5.96-5.44 3.13 0 5.57 2.23 5.57 5.2 0 3.1-1.93 5.6-4.69 5.6-.82.02-1.6-.36-2.07-1.03l-.56 2.14a9.98 9.98 0 01-1.12 2.36c.87.25 1.79.38 2.7.37A9.02 9.02 0 0021 12c0-4.97-4.04-9-9.03-9' /></svg>							</a>
						</li>
						<li>
							<a href="https://www.youtube.com/user/drugscom" target='_blank' rel='noopener' class="ddc-share-icon ddc-share-icon-youtube">
								<span class='ddc-share-icon-label'>Follow Drugs.com on YouTube</span> <svg class='ddc-icon ddc-icon-youtube' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M12.25 5c.57 0 2.05.01 3.58.07l.5.01c1.45.06 2.85.16 3.48.32.86.22 1.54.86 1.77 1.68.38 1.33.42 3.96.42 4.5v.18c0 .53-.04 3.16-.42 4.5-.23.81-.9 1.46-1.77 1.68-1.33.34-6.12.39-7.46.4h-.71c-1.33-.01-6.12-.06-7.45-.4a2.45 2.45 0 01-1.77-1.69A22.62 22.62 0 012 11.76v-.19c0-.53.04-3.16.42-4.49.23-.82.9-1.46 1.77-1.68.63-.16 2.03-.26 3.47-.32l.51-.01C9.7 5 11.18 5 11.75 5zm-2.3 3.85v5.63l5.23-2.81-5.23-2.82z' /></svg>							</a>
						</li>
						<li>
							<a href="/newsletters/" title='Drugs.com RSS Feeds' class="ddc-share-icon">
								<span class='ddc-share-icon-label'>Subscribe to our Newsletters</span> <svg class='ddc-icon ddc-icon-email' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M20 4.25c.92 0 1.67.7 1.74 1.6l.01.15v12c0 .92-.7 1.67-1.6 1.74l-.15.01H4c-.92 0-1.67-.7-1.74-1.6L2.25 18V6c0-.92.7-1.67 1.6-1.74L4 4.25h16zm-.17 1.77a.75.75 0 00-1.06-.1L12 11.52l-6.77-5.6-.1-.06a.75.75 0 00-.86 1.22l7.25 6 .1.07c.27.15.61.13.86-.07l7.25-6L19.8 7a.75.75 0 00.02-.98z' /></svg>							</a>
						</li>
					</ul>
					<p class='ddc-mgb-1'><a href="/newsletters/">Subscribe</a> to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates.</p>
				</div>
			</div>

		</div>

		<div class='footer-description'>
			<p><strong>Drugs.com</strong> provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated 1 July 2021), Cerner Multum&trade; (updated 1 July 2021), ASHP (updated 30 June 2021) and others.</p>
		</div>

		<div class='footer-info ddc-clearfix'>

			<div class='footPrivacy'>
				<ul class="site-privacy ddc-list-unstyled ddc-mg-0">
					<li class="privacy-logo logo-truste ddc-clearfix">
						<a href='//privacy.truste.com/privacy-seal/validation?rid=d18cba4a-afc4-4863-af81-8262bb120271' target='_blank' rel='noopener'>
							<img data-lazy-load data-src='//privacy-policy.truste.com/privacy-seal/seal?rid=d18cba4a-afc4-4863-af81-8262bb120271' src='/img/pixel.gif' width='142' height='45' alt='TRUSTe'>
						</a>
					</li>
					<li class="privacy-logo logo-adchoices ddc-clearfix">
						<a href="/support/privacy/advertising.html">
							<img data-lazy-load data-src='/img/logo/vendor/adchoices-logomark.png' src='/img/pixel.gif' width='40' height='42' alt='AdChoices'>
							<span>
								<b>Ad Choices</b>
							</span>
						</a>
					</li>
					<li class="privacy-logo logo-honcode ddc-clearfix">
						<img data-lazy-load data-src='/img/logo/vendor/honcode-2020.png' src='/img/pixel.gif' width='43' height='60' alt='HonCode'>
						<span>We comply with the HONcode standard for trustworthy health information. <a class='ddc-text-nowrap' href='//www.hon.ch/HONcode/Conduct.html?HONConduct756274' target='_blank' rel='noopener nofollow'>Verify here</a></span>
					</li>
					<li class="site-info">
						<span>Copyright &copy; 2000-2021 Drugs.com. <span class='ddc-display-block'>All rights reserved.</span></span>
					</li>
				</ul>
			</div>
		</div>
	</div>
</footer>
<div class='ddc-social-share'></div>


<!-- Global JS var for configuration data/settings -->
<script>SITECONFIG = {"agent":{"isMobile":false},"user":{"userid":0,"modal":{"login":"/api/user/modal/login/"},"consent":{"skip":true,"api":{"url":"/api/user/"}}},"page":{"section":"monograph","subsection":"","doc":"content","delayedCss":["/bundle/css/component/component.share.min.9d6804aa.css"],"delayedScripts":[],"image":{"lazyLoad":{"selector":"[data-lazy-load]","screens":1,"delay":2000}},"mailTo":{"delay":5000,"location":"/support/email-mailto.html"}},"form":{"recaptcha":{"sitekey":"6Ld-iSYTAAAAAOO0VTEwVl71HtvrFoSlPSibGr4g","callback":"DDC_RECAPTCHA_CALLBACK"}},"dwLog":{"a":1472,"b":"null","c":"523,954,10139,1254,802,974","d":"87,125,134,337","e":"2545","f":4974,"h":0,"i":"default","k":"523,954,10139,1254,802,974","l":"","m":"","n":"","o":"","p":0,"q":"drugs/monograph"},"drugs":[{"ddc_id":1472,"brand_name_id":0,"mtm_id":"d04534","generic_name":"linezolid systemic","name":"linezolid"}],"options":{"recordSelection":false,"classifyLists":{"wrapper":"#content","countHtmlItems":false,"numItems":{"short":10,"medium":25,"long":50},"charLimit":{"paragraph":30,"content":350}}},"subscribe":null,"dictionary":[],"share":{"sticky":{"target":".ddc-social-share"},"types":[{"title":"Facebook","label":"Share on Facebook","cssClass":"ddc-share-icon ddc-share-icon-facebook","labelClass":"ddc-share-icon-label","icon":"<svg class='ddc-icon ddc-icon-facebook' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M14 6.54c-2.06 0-3.4 1.25-3.4 3.52v2H8.3v2.61h2.3V21A9.04 9.04 0 013 12.05C3 7.05 7.03 3 12 3s9 4.05 9 9.05c0 4.53-3.3 8.27-7.6 8.95v-6.33h2.1l.4-2.62h-2.5v-1.7c0-.7.35-1.4 1.47-1.4h1.14V6.7s-1.03-.17-2.02-.17z' /></svg>","shareUrl":"https://www.facebook.com/sharer/sharer.php?u=SHAREURL","width":600,"height":500},{"title":"Twitter","label":"Share on Twitter","cssClass":"ddc-share-icon ddc-share-icon-twitter","labelClass":"ddc-share-icon-label","icon":"<svg class='ddc-icon ddc-icon-twitter' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M8.66 19.63a10.44 10.44 0 0010.5-10.5v-.5A7.7 7.7 0 0021 6.74c-.67.3-1.39.5-2.12.58a3.73 3.73 0 001.64-2.04c-.72.43-1.52.74-2.34.9a3.7 3.7 0 00-6.3 3.36 10.46 10.46 0 01-7.61-3.85 3.69 3.69 0 001.14 4.9 3.66 3.66 0 01-1.63-.45v.04a3.7 3.7 0 002.9 3.64 3.7 3.7 0 01-1.63.06 3.69 3.69 0 003.42 2.53 7.4 7.4 0 01-4.6 1.64 8 8 0 01-.87-.07 10.45 10.45 0 005.66 1.63' /></svg>","shareUrl":"https://twitter.com/intent/tweet?text=SHARETITLE&url=SHAREURL","width":600,"height":420},{"title":"Email","label":"Email to a friend","cssClass":"ddc-share-icon ddc-share-icon-email","labelClass":"ddc-share-icon-label","icon":"<svg class='ddc-icon ddc-icon-email' width='16' height='16' viewBox='0 0 24 24' aria-hidden='true' focusable='false' xmlns='http://www.w3.org/2000/svg'><path d='M20 4.25c.92 0 1.67.7 1.74 1.6l.01.15v12c0 .92-.7 1.67-1.6 1.74l-.15.01H4c-.92 0-1.67-.7-1.74-1.6L2.25 18V6c0-.92.7-1.67 1.6-1.74L4 4.25h16zm-.17 1.77a.75.75 0 00-1.06-.1L12 11.52l-6.77-5.6-.1-.06a.75.75 0 00-.86 1.22l7.25 6 .1.07c.27.15.61.13.86-.07l7.25-6L19.8 7a.75.75 0 00.02-.98z' /></svg>","mailUrl":"mailto:?body=https%3A%2F%2Fwww.drugs.com%2Fmonograph%2Flinezolid.html","width":600,"height":420}],"mednotes":{"apiUrl":"/mednotes/api/modal","saveButton":"data-modal-mednotes-save"}},"ads":{"section":"drugs/monograph","ugc":false,"display":{"mobile":false,"logUrl":"/api/logger/ads/","units":[]},"injection":{"placeholder":[{"selector":"[data-ad-placeholder=TAP_NATIVE_AD]","ad":{"type":"TapNative","format":"fluid","buffer":0,"lazy":0.75},"buffer":{"before":800,"after":1000}}],"lazy":0.75,"maximum":{"ads":10,"tags":1000},"container":"#content","start":[".nav-tabs","h2","h1"],"stop":[".footer-feature","#sidebar"],"last":{"buffer":500},"insert":["section","h2","h3","h4","h5","p","ol","ul","table",".ddc-legend",".nav-tabs",".nav-tabs-group",".responsive-table-wrap"],"blacklist":["form","ol","ul","dl","table",".blackboxWarning",".column-split",".ddc-accordion",".ddc-box",".ddc-card",".ddc-card-group",".ddc-form-inline",".ddc-expand-read-more",".ddc-grid",".ddc-legend",".ddc-media",".ddc-navtree",".ddc-notification",".ddc-paging",".ddc-toc",".ddc-widget-calculator",".injection-ignore-inside",".nav-tabs",".nav-tabs-group",".paging-list-wrap",".responsive-table-wrap",".snippet",".ddc-official-answer"],"list":[{"type":"EHS","width":300,"height":250,"buffer":-1,"viewportPercent":75,"lazy":0.75,"data":{"size":"300x250","vpos":"b","hpos":"r","site":"ehs.pro.drugs.drugs","iprof":"md","ims1":"i18","ims2":"p40","ims3":"d5","drg":["linezolid"],"drc":["oxazolidinone_antibiotics"],"dra":1}}]}},"nativeApp":{"version":0,"appSrc":"","memoryWarning":{"log":0,"ads":1}},"fixable":{"items":[{"targetSelector":".topbanner-wrap","delay":2500,"leaderboard":true},{"containerSelector":"#contentWrap","targetSelector":"#sideBoxStackedAd-1","delay":2500,"maximizeStickyHeight":true}]},"toc":[],"interaction":{"isDeferredSave":false,"url":"/interaction/list/","param":{"drugList":"drug_list","listId":"interaction_list_id"}},"identityLink":{"api":{"url":"/api/user/"},"cookie":{"link":"pbjs_identitylink","data":"pbjs_identitydata"}},"moreResources":{"list-data-resources-consumer":"<li><a onclick='window.location=\"/cons/linezolid-intravenous.html\";return false;' href='#'>Linezolid Intravenous <span>(Advanced Reading)</span></a></li> <li><a onclick='window.location=\"/cons/linezolid-intravenous-oral.html\";return false;' href='#'>Linezolid Intravenous, Oral <span>(Advanced Reading)</span></a></li> <li><a onclick='window.location=\"/cdi/linezolid-injection.html\";return false;' href='#'>Linezolid Injection</a></li> <li><a onclick='window.location=\"/cdi/linezolid-suspension.html\";return false;' href='#'>Linezolid Suspension</a></li> <li><a onclick='window.location=\"/cdi/linezolid-tablets.html\";return false;' href='#'>Linezolid Tablets</a></li>"}};</script>

<script src='//www.google-analytics.com/analytics.js' defer></script>
<script>
(function(i,r){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();})(window,'ga');
ga('create', 'UA-78451-2', 'auto', {'siteSpeedSampleRate': 30, 'useAmpClientId': true});
ga('require', 'linkid', 'linkid.js');
ga('require', 'displayfeatures');
ga('set', 'anonymizeIp', true);
ga('set', {"dimension46":"no","dimension47":"no","dimension1":"1472-0","dimension26":";523;954;10139;1254;802;974;","dimension25":";4286;4292;6067;4295;","dimension11":"No","dimension43":"index\/follow","contentGroup1":"Drug","contentGroup2":"AHFS Monographs","dimension24":"AHFS Monographs","dimension16":"HCP","dimension17":"English","contentGroup3":"Very Long Page","dimension15":"No","dimension18":"Web","dimension59":"Yes"});
ga('send', 'pageview', {});
</script>
<script>
window.dataLayer = window.dataLayer || [];
window.dataLayer.push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
window.dataLayer.push({"event":"pageview","drug_name":"linezolid","drug_id":"1472-0","ddc_id":"1472","condition_ids":";523;954;10139;1254;802;974;","zone_ids":";4286;4292;6067;4295;","user_signed_in":"No","user_ilink":"No","page_index_status":"index/follow","page_orphan":"No","page_traffic_op":"No","content_type":"Drug","content_section":"AHFS Monographs","content_sub_section":"AHFS Monographs","content_audience":"HCP","content_language":"English","content_size":"Very Long Page","content_ugc":"No","app_source":"Web","ads_pro":"Yes"});

</script>
<script src='//www.googletagmanager.com/gtm.js?id=GTM-MZ4MM39' defer></script>

<script>
var AD_Z = 'drugs/monograph';
var AD_T = "_('ugc','0')_('c1',['4286','4292','6067','4295'])_('d','1472')_('b','0')_('c2',['523','954','10139','1254','802','974'])_('dc',['2545'])_('mi','1')_('rx','1')_('c2o',['523','954','10139','1254','802','974'])";
var AD_PT = "_('ppro', ['md','i18','p40','d5'])";
</script>
<script src='/bundle/js/polyfill.min.b17ad879.js' defer></script>
<script src='/bundle/js/launch-base.min.100d9649.js' defer></script>
<script src='/bundle/js/module-subscribe.min.305e1074.js' defer></script>

<script>
var _comscore = _comscore || [];
_comscore.push({c1: '2', c2: '9355535'});
</script>
<script src='//sb.scorecardresearch.com/beacon.js' defer></script>
<noscript><img src='https://sb.scorecardresearch.com/p?c1=2&amp;c2=9355535&amp;cv=2.0&amp;cj=1' alt=''></noscript>
<div id='drugs-drugs-3' class='display-ad display-ad-inter'>
<script>
var ehs_ad_called = ++ehs_ad_called || 1;
</script>
</div>
<script src='//ads.ehealthcaresolutions.com/a/?adid=drugs-drugs-3&slotid=3&url=www.drugs.com%2Fmonograph%2Flinezolid.html&size=inter&vpos=t&hpos=r&site=ehs.pro.drugs.drugs&iprof=md&ims1=i18&ims2=p40&ims3=d5&drg=linezolid&drc=oxazolidinone_antibiotics&dra=1' defer></script>
<script>
(function(){/*
 Copyright The Closure Library Authors.
 SPDX-License-Identifier: Apache-2.0
*/
'use strict';var g=function(a){var b=0;return function(){return b<a.length?{done:!1,value:a[b++]}:{done:!0}}},l=this||self,m=/^[\w+/_-]+[=]{0,2}$/,p=null,q=function(){},r=function(a){var b=typeof a;if("object"==b)if(a){if(a instanceof Array)return"array";if(a instanceof Object)return b;var c=Object.prototype.toString.call(a);if("[object Window]"==c)return"object";if("[object Array]"==c||"number"==typeof a.length&&"undefined"!=typeof a.splice&&"undefined"!=typeof a.propertyIsEnumerable&&!a.propertyIsEnumerable("splice"))return"array";
if("[object Function]"==c||"undefined"!=typeof a.call&&"undefined"!=typeof a.propertyIsEnumerable&&!a.propertyIsEnumerable("call"))return"function"}else return"null";else if("function"==b&&"undefined"==typeof a.call)return"object";return b},u=function(a,b){function c(){}c.prototype=b.prototype;a.prototype=new c;a.prototype.constructor=a};var v=function(a,b){Object.defineProperty(l,a,{configurable:!1,get:function(){return b},set:q})};var y=function(a,b){this.b=a===w&&b||"";this.a=x},x={},w={};var aa=function(a,b){a.src=b instanceof y&&b.constructor===y&&b.a===x?b.b:"type_error:TrustedResourceUrl";if(null===p)b:{b=l.document;if((b=b.querySelector&&b.querySelector("script[nonce]"))&&(b=b.nonce||b.getAttribute("nonce"))&&m.test(b)){p=b;break b}p=""}b=p;b&&a.setAttribute("nonce",b)};var z=function(){return Math.floor(2147483648*Math.random()).toString(36)+Math.abs(Math.floor(2147483648*Math.random())^+new Date).toString(36)};var A=function(a,b){b=String(b);"application/xhtml+xml"===a.contentType&&(b=b.toLowerCase());return a.createElement(b)},B=function(a){this.a=a||l.document||document};B.prototype.appendChild=function(a,b){a.appendChild(b)};var C=function(a,b,c,d,e,f){try{var k=a.a,h=A(a.a,"SCRIPT");h.async=!0;aa(h,b);k.head.appendChild(h);h.addEventListener("load",function(){e();d&&k.head.removeChild(h)});h.addEventListener("error",function(){0<c?C(a,b,c-1,d,e,f):(d&&k.head.removeChild(h),f())})}catch(n){f()}};var ba=l.atob("aHR0cHM6Ly93d3cuZ3N0YXRpYy5jb20vaW1hZ2VzL2ljb25zL21hdGVyaWFsL3N5c3RlbS8xeC93YXJuaW5nX2FtYmVyXzI0ZHAucG5n"),ca=l.atob("WW91IGFyZSBzZWVpbmcgdGhpcyBtZXNzYWdlIGJlY2F1c2UgYWQgb3Igc2NyaXB0IGJsb2NraW5nIHNvZnR3YXJlIGlzIGludGVyZmVyaW5nIHdpdGggdGhpcyBwYWdlLg=="),da=l.atob("RGlzYWJsZSBhbnkgYWQgb3Igc2NyaXB0IGJsb2NraW5nIHNvZnR3YXJlLCB0aGVuIHJlbG9hZCB0aGlzIHBhZ2Uu"),ea=function(a,b,c){this.b=a;this.f=new B(this.b);this.a=null;this.c=[];this.g=!1;this.i=b;this.h=c},F=function(a){if(a.b.body&&!a.g){var b=
function(){D(a);l.setTimeout(function(){return E(a,3)},50)};C(a.f,a.i,2,!0,function(){l[a.h]||b()},b);a.g=!0}},D=function(a){for(var b=G(1,5),c=0;c<b;c++){var d=H(a);a.b.body.appendChild(d);a.c.push(d)}b=H(a);b.style.bottom="0";b.style.left="0";b.style.position="fixed";b.style.width=G(100,110).toString()+"%";b.style.zIndex=G(2147483544,2147483644).toString();b.style["background-color"]=I(249,259,242,252,219,229);b.style["box-shadow"]="0 0 12px #888";b.style.color=I(0,10,0,10,0,10);b.style.display=
"flex";b.style["justify-content"]="center";b.style["font-family"]="Roboto, Arial";c=H(a);c.style.width=G(80,85).toString()+"%";c.style.maxWidth=G(750,775).toString()+"px";c.style.margin="24px";c.style.display="flex";c.style["align-items"]="flex-start";c.style["justify-content"]="center";d=A(a.f.a,"IMG");d.className=z();d.src=ba;d.style.height="24px";d.style.width="24px";d.style["padding-right"]="16px";var e=H(a),f=H(a);f.style["font-weight"]="bold";f.textContent=ca;var k=H(a);k.textContent=da;J(a,
e,f);J(a,e,k);J(a,c,d);J(a,c,e);J(a,b,c);a.a=b;a.b.body.appendChild(a.a);b=G(1,5);for(c=0;c<b;c++)d=H(a),a.b.body.appendChild(d),a.c.push(d)},J=function(a,b,c){for(var d=G(1,5),e=0;e<d;e++){var f=H(a);b.appendChild(f)}b.appendChild(c);c=G(1,5);for(d=0;d<c;d++)e=H(a),b.appendChild(e)},G=function(a,b){return Math.floor(a+Math.random()*(b-a))},I=function(a,b,c,d,e,f){return"rgb("+G(Math.max(a,0),Math.min(b,255)).toString()+","+G(Math.max(c,0),Math.min(d,255)).toString()+","+G(Math.max(e,0),Math.min(f,
255)).toString()+")"},H=function(a){a=A(a.f.a,"DIV");a.className=z();return a},E=function(a,b){0>=b||null!=a.a&&0!=a.a.offsetHeight&&0!=a.a.offsetWidth||(fa(a),D(a),l.setTimeout(function(){return E(a,b-1)},50))},fa=function(a){var b=a.c;var c="undefined"!=typeof Symbol&&Symbol.iterator&&b[Symbol.iterator];b=c?c.call(b):{next:g(b)};for(c=b.next();!c.done;c=b.next())(c=c.value)&&c.parentNode&&c.parentNode.removeChild(c);a.c=[];(b=a.a)&&b.parentNode&&b.parentNode.removeChild(b);a.a=null};var ia=function(a,b,c,d,e){var f=ha(c),k=function(n){n.appendChild(f);l.setTimeout(function(){f?(0!==f.offsetHeight&&0!==f.offsetWidth?b():a(),f.parentNode&&f.parentNode.removeChild(f)):a()},d)},h=function(n){document.body?k(document.body):0<n?l.setTimeout(function(){h(n-1)},e):b()};h(3)},ha=function(a){var b=document.createElement("div");b.className=a;b.style.width="1px";b.style.height="1px";b.style.position="absolute";b.style.left="-10000px";b.style.top="-10000px";b.style.zIndex="-10000";return b};var K={},L=null;var M=function(){},N="function"==typeof Uint8Array,O=function(a,b){a.b=null;b||(b=[]);a.j=void 0;a.f=-1;a.a=b;a:{if(b=a.a.length){--b;var c=a.a[b];if(!(null===c||"object"!=typeof c||Array.isArray(c)||N&&c instanceof Uint8Array)){a.g=b-a.f;a.c=c;break a}}a.g=Number.MAX_VALUE}a.i={}},P=[],Q=function(a,b){if(b<a.g){b+=a.f;var c=a.a[b];return c===P?a.a[b]=[]:c}if(a.c)return c=a.c[b],c===P?a.c[b]=[]:c},R=function(a,b,c){a.b||(a.b={});if(!a.b[c]){var d=Q(a,c);d&&(a.b[c]=new b(d))}return a.b[c]};
M.prototype.h=N?function(){var a=Uint8Array.prototype.toJSON;Uint8Array.prototype.toJSON=function(){var b;void 0===b&&(b=0);if(!L){L={};for(var c="ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789".split(""),d=["+/=","+/","-_=","-_.","-_"],e=0;5>e;e++){var f=c.concat(d[e].split(""));K[e]=f;for(var k=0;k<f.length;k++){var h=f[k];void 0===L[h]&&(L[h]=k)}}}b=K[b];c=[];for(d=0;d<this.length;d+=3){var n=this[d],t=(e=d+1<this.length)?this[d+1]:0;h=(f=d+2<this.length)?this[d+2]:0;k=n>>2;n=(n&
3)<<4|t>>4;t=(t&15)<<2|h>>6;h&=63;f||(h=64,e||(t=64));c.push(b[k],b[n],b[t]||"",b[h]||"")}return c.join("")};try{return JSON.stringify(this.a&&this.a,S)}finally{Uint8Array.prototype.toJSON=a}}:function(){return JSON.stringify(this.a&&this.a,S)};var S=function(a,b){return"number"!==typeof b||!isNaN(b)&&Infinity!==b&&-Infinity!==b?b:String(b)};M.prototype.toString=function(){return this.a.toString()};var T=function(a){O(this,a)};u(T,M);var U=function(a){O(this,a)};u(U,M);var ja=function(a,b){this.c=new B(a);var c=R(b,T,5);c=new y(w,Q(c,4)||"");this.b=new ea(a,c,Q(b,4));this.a=b},ka=function(a,b,c,d){b=new T(b?JSON.parse(b):null);b=new y(w,Q(b,4)||"");C(a.c,b,3,!1,c,function(){ia(function(){F(a.b);d(!1)},function(){d(!0)},Q(a.a,2),Q(a.a,3),Q(a.a,1))})};var la=function(a,b){V(a,"internal_api_load_with_sb",function(c,d,e){ka(b,c,d,e)});V(a,"internal_api_sb",function(){F(b.b)})},V=function(a,b,c){a=l.btoa(a+b);v(a,c)},W=function(a,b,c){for(var d=[],e=2;e<arguments.length;++e)d[e-2]=arguments[e];e=l.btoa(a+b);e=l[e];if("function"==r(e))e.apply(null,d);else throw Error("API not exported.");};var X=function(a){O(this,a)};u(X,M);var Y=function(a){this.h=window;this.a=a;this.b=Q(this.a,1);this.f=R(this.a,T,2);this.g=R(this.a,U,3);this.c=!1};Y.prototype.start=function(){ma();var a=new ja(this.h.document,this.g);la(this.b,a);na(this)};
var ma=function(){var a=function(){if(!l.frames.googlefcPresent)if(document.body){var b=document.createElement("iframe");b.style.display="none";b.style.width="0px";b.style.height="0px";b.style.border="none";b.style.zIndex="-1000";b.style.left="-1000px";b.style.top="-1000px";b.name="googlefcPresent";document.body.appendChild(b)}else l.setTimeout(a,5)};a()},na=function(a){var b=Date.now();W(a.b,"internal_api_load_with_sb",a.f.h(),function(){var c;var d=a.b,e=l[l.btoa(d+"loader_js")];if(e){e=l.atob(e);
e=parseInt(e,10);d=l.btoa(d+"loader_js").split(".");var f=l;d[0]in f||"undefined"==typeof f.execScript||f.execScript("var "+d[0]);for(;d.length&&(c=d.shift());)d.length?f[c]&&f[c]!==Object.prototype[c]?f=f[c]:f=f[c]={}:f[c]=null;c=Math.abs(b-e);c=1728E5>c?0:c}else c=-1;0!=c&&(W(a.b,"internal_api_sb"),Z(a,Q(a.a,6)))},function(c){Z(a,c?Q(a.a,4):Q(a.a,5))})},Z=function(a,b){a.c||(a.c=!0,a=new l.XMLHttpRequest,a.open("GET",b,!0),a.send())};(function(a,b){l[a]=function(c){for(var d=[],e=0;e<arguments.length;++e)d[e-0]=arguments[e];l[a]=q;b.apply(null,d)}})("__d3lUW8vwsKlB__",function(a){"function"==typeof window.atob&&(a=window.atob(a),a=new X(a?JSON.parse(a):null),(new Y(a)).start())});}).call(this);

window.__d3lUW8vwsKlB__("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");
</script>
</body>
</html>
